CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022

Deborah Dowell, Kathleen R Ragan, Christopher M Jones, Grant T Baldwin, Roger Chou, Deborah Dowell, Kathleen R Ragan, Christopher M Jones, Grant T Baldwin, Roger Chou

Abstract

This guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016 (MMWR Recomm Rep 2016;65[No. RR-1]:1-49) and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1-3 months), and chronic (duration of >3 months) pain. The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative or end-of-life care. The guideline addresses the following four areas: 1) determining whether or not to initiate opioids for pain, 2) selecting opioids and determining opioid dosages, 3) deciding duration of initial opioid prescription and conducting follow-up, and 4) assessing risk and addressing potential harms of opioid use. CDC developed the guideline using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. Recommendations are based on systematic reviews of the scientific evidence and reflect considerations of benefits and harms, patient and clinician values and preferences, and resource allocation. CDC obtained input from the Board of Scientific Counselors of the National Center for Injury Prevention and Control (a federally chartered advisory committee), the public, and peer reviewers. CDC recommends that persons with pain receive appropriate pain treatment, with careful consideration of the benefits and risks of all treatment options in the context of the patient's circumstances. Recommendations should not be applied as inflexible standards of care across patient populations. This clinical practice guideline is intended to improve communication between clinicians and patients about the benefits and risks of pain treatments, including opioid therapy; improve the effectiveness and safety of pain treatment; mitigate pain; improve function and quality of life for patients with pain; and reduce risks associated with opioid pain therapy, including opioid use disorder, overdose, and death.

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest; no significant conflicts of interest were disclosed.

References

    1. Chou R, Hartung D, Turner J, et al. Opioid treatments for chronic pain. Comparative effectiveness review no. 229. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
    1. Skelly A, Chou R, Dettori J, et al. Noninvasive nonpharmacological treatment for chronic pain: a systematic review update. Comparative effectiveness review no. 227. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
    1. McDonagh M, Selph S, Buckley D, et al. Nonopioid pharmacologic treatments for chronic pain. Comparative effectiveness review no. 228. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
    1. Chou R, Wagner J, Ahmed A, et al. Treatments for acute pain: a systematic review. Comparative effectiveness review no. 240. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
    1. Halker Singh R, VanderPluym J, Morrow A, et al. Acute treatments for episodic migraine. Comparative effectiveness review no. 239. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
    1. Skelly AC, Chou R, Dettori JR, et al. Noninvasive nonpharmacological treatment for chronic pain: a systematic review. Comparative effectiveness review no. 209. Rockville, MD: Agency for Healthcare Research and Quality; 2018.10.23970/AHRQEPCCER209
    1. Chou R, Deyo R, Devine B, et al. The effectiveness and risks of long-term opioid treatment of chronic pain. Evidence report/technology assessment no. 218. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
    1. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1):1–49. 10.15585/mmwr.rr6501e1
    1. Chou R, Deyo R, Friedly J, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. Ann Intern Med 2017;166:480–92. 10.7326/M16-2458
    1. Fairbank JC, Pynsent PB. The Oswestry Disability Index. Spine 2000;25:2940–523. 10.1097/00007632-200011150-00017
    1. Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine 1983;8:141–4. 10.1097/00007632-198303000-00004
    1. Ostelo RWJG, Deyo RA, Stratford P, et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine 2008;33:90–4. 10.1097/BRS.0b013e31815e3a10
    1. Jayadevappa R, Cook R, Chhatre S. Minimal important difference to infer changes in health-related quality of life—a systematic review. J Clin Epidemiol 2017;89:188–98. 10.1016/j.jclinepi.2017.06.009
    1. Keurentjes JC, Van Tol FR, Fiocco M, Schoones JW, Nelissen RG. Minimal clinically important differences in health-related quality of life after total hip or knee replacement: a systematic review. Bone Joint Res 2012;1:71–7. 10.1302/2046-3758.15.2000065
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 1994;23:129–38.
    1. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83. 10.1097/00005650-199206000-00002
    1. Furlan A, Chaparro LE, Irvin E, Mailis-Gagnon A. A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. Pain Res Manag 2011;16:337–51. 10.1155/2011/465281
    1. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015;156:569–76. 10.1097/01.j.pain.0000460357.01998.f1
    1. Veiga DR, Monteiro-Soares M, Mendonça L, Sampaio R, Castro-Lopes JM, Azevedo LF. Effectiveness of opioids for chronic noncancer pain: a 2-year multicenter, prospective cohort study with propensity score matching. J Pain 2019;20:706–15. 10.1016/j.jpain.2018.12.007
    1. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Prescription of long-acting opioids and mortality in patients with chronic noncancer pain. JAMA 2016;315:2415–23. 10.1001/jama.2016.7789
    1. Scherrer JF, Salas J, Copeland LA, et al. Prescription opioid duration, dose, and increased risk of depression in 3 large patient populations. Ann Fam Med 2016;14:54–62. 10.1370/afm.1885
    1. Scherrer JF, Salas J, Sullivan MD, et al. The influence of prescription opioid use duration and dose on development of treatment resistant depression. Prev Med 2016;91:110–6. 10.1016/j.ypmed.2016.08.003
    1. Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med 2017;14:e1002396. 10.1371/journal.pmed.1002396
    1. Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case-control study. Ann Intern Med 2018;169:732–4. 10.7326/M18-1136
    1. Peckham AM, Fairman KA, Sclar DA. All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: a retrospective cohort analysis of a commercially insured US population. Drug Saf 2018;41:213–28. 10.1007/s40264-017-0595-1
    1. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010;152:85–92. 10.7326/0003-4819-152-2-201001190-00006
    1. Hernandez I, He M, Brooks MM, Zhang Y. Exposure-response association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in Medicare Part D beneficiaries. JAMA Netw Open 2018;1:e180919. 10.1001/jamanetworkopen.2018.0919
    1. Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ 2017;356:j760. 10.1136/bmj.j760
    1. Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA 2018;319:872–82. 10.1001/jama.2018.0899
    1. Naliboff BD, Wu SM, Schieffer B, et al. A randomized trial of 2 prescription strategies for opioid treatment of chronic nonmalignant pain. J Pain 2011;12:288–96. 10.1016/j.jpain.2010.09.003
    1. Food and Drug Administration. Public health advisory: important information for the safe use of Fentora (fentanyl buccal tablets). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2007.
    1. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005;6:432–42. 10.1111/j.1526-4637.2005.00072.x
    1. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain 2008;9:360–72. 10.1016/j.jpain.2007.11.014
    1. Coffin PO, Behar E, Rowe C, et al. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med 2016;165:245–52. 10.7326/M15-2771
    1. Sullivan MD, Turner JA, DiLodovico C, D’Appollonio A, Stephens K, Chan Y-F. Prescription opioid taper support for outpatients with chronic pain: a randomized controlled trial. J Pain 2017;18:308–18. 10.1016/j.jpain.2016.11.003
    1. James JR, Scott JM, Klein JW, et al. Mortality after discontinuation of primary care-based chronic opioid therapy for pain: a retrospective cohort study. J Gen Intern Med 2019;34:2749–55. 10.1007/s11606-019-05301-2
    1. Mark TL, Parish W. Opioid medication discontinuation and risk of adverse opioid-related health care events. J Subst Abuse Treat 2019;103:58–63. 10.1016/j.jsat.2019.05.001
    1. Santilli V, Beghi E, Finucci S. Chiropractic manipulation in the treatment of acute back pain and sciatica with disc protrusion: a randomized double-blind clinical trial of active and simulated spinal manipulations. Spine J 2006;6:131–7. 10.1016/j.spinee.2005.08.001
    1. Shin J-S, Ha I-H, Lee J, et al. Effects of motion style acupuncture treatment in acute low back pain patients with severe disability: a multicenter, randomized, controlled, comparative effectiveness trial. Pain 2013;154:1030–7. 10.1016/j.pain.2013.03.013
    1. Ebbert JO, Philpot LM, Clements CM, et al. Attitudes, beliefs, practices, and concerns among clinicians prescribing opioids in a large academic institution. Pain Med 2018;19:1790–8. 10.1093/pm/pnx140
    1. Kennedy-Hendricks A, Busch SH, McGinty EE, et al. Primary care physicians’ perspectives on the prescription opioid epidemic. Drug Alcohol Depend 2016;165:61–70. 10.1016/j.drugalcdep.2016.05.010
    1. Razouki Z, Khokhar BA, Philpot LM, Ebbert JO. Attributes, attitudes, and practices of clinicians concerned with opioid prescribing. Pain Med 2019;20:1934–41. 10.1093/pm/pny204
    1. Lin DH, Lucas E, Murimi IB, et al. Physician attitudes and experiences with Maryland’s prescription drug monitoring program (PDMP). Addiction 2017;112:311–9. 10.1111/add.13620
    1. Goshua A, Craigie S, Guyatt GH, et al. Patient values and preferences regarding opioids for chronic noncancer pain: a systematic review. Pain Med 2018;19:2469–80. 10.1093/pm/pnx274
    1. Pain News Network. 2017 CDC Survey Results. 2017.
    1. Rosenberg EI, Genao I, Chen I, et al. Complementary and alternative medicine use by primary care patients with chronic pain. Pain Med 2008;9:1065–72. 10.1111/j.1526-4637.2008.00477.x
    1. Francois SJ, Lanier VM, Marich AV, Wallendorf M, Van Dillen LR. A cross-sectional study assessing treatment preference of people with chronic low back pain. Arch Phys Med Rehabil 2018;99:2496–503. 10.1016/j.apmr.2018.04.027
    1. Dima A, Lewith GT, Little P, Moss-Morris R, Foster NE, Bishop FL. Identifying patients’ beliefs about treatments for chronic low back pain in primary care: a focus group study. Br J Gen Pract 2013;63:e490–8. 10.3399/bjgp13X669211
    1. Cottrell E, Foster NE, Porcheret M, Rathod T, Roddy E. GPs’ attitudes, beliefs and behaviours regarding exercise for chronic knee pain: a questionnaire survey. BMJ Open 2017;7:e014999. 10.1136/bmjopen-2016-014999
    1. Cottrell E, Roddy E, Foster NE. The attitudes, beliefs and behaviours of GPs regarding exercise for chronic knee pain: a systematic review. BMC Fam Pract 2010;11:4. 10.1186/1471-2296-11-4
    1. Driver C, Kean B, Oprescu F, Lovell GP. Knowledge, behaviors, attitudes and beliefs of physiotherapists towards the use of psychological interventions in physiotherapy practice: a systematic review. Disabil Rehabil 2017;39:2237–49. 10.1080/09638288.2016.1223176
    1. Cowell I, O’Sullivan P, O’Sullivan K, Poyton R, McGregor A, Murtagh G. Perceptions of physiotherapists towards the management of non-specific chronic low back pain from a biopsychosocial perspective: A qualitative study. Musculoskelet Sci Pract 2018;38:113–9. 10.1016/j.msksp.2018.10.006
    1. Holden MA, Nicholls EE, Young J, Hay EM, Foster NE. UK-based physical therapists’ attitudes and beliefs regarding exercise and knee osteoarthritis: findings from a mixed-methods study. Arthritis Rheum 2009;61:1511–21. 10.1002/art.24829
    1. Sierpina V, Levine R, Astin J, Tan A. Use of mind-body therapies in psychiatry and family medicine faculty and residents: attitudes, barriers, and gender differences. Explore (NY) 2007;3:129–35. 10.1016/j.explore.2006.12.001
    1. Heyward J, Jones CM, Compton WM, et al. Coverage of nonpharmacologic treatments for low back pain among US public and private insurers. JAMA Netw Open 2018;1:e183044. 10.1001/jamanetworkopen.2018.3044
    1. Mühlbacher AC, Junker U, Juhnke C, et al. Chronic pain patients’ treatment preferences: a discrete-choice experiment. Eur J Health Econ 2015;16:613–28. 10.1007/s10198-014-0614-4
    1. Turk D, Boeri M, Abraham L, et al. Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: a discrete-choice experiment. Osteoarthritis Cartilage 2020;28:1202–13. 10.1016/j.joca.2020.06.006
    1. Patel T, Chang F, Mohammed HT, et al. Knowledge, perceptions, and attitudes toward chronic pain and its management: a cross-sectional survey of frontline pharmacists in Ontario, Canada. PLoS One 2016;11:e0157151. 10.1371/journal.pone.0157151
    1. Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective. Appl Health Econ Health Policy 2013;11:219–36. 10.1007/s40258-013-0031-3
    1. Hallway A, Vu J, Lee J, et al. Patient satisfaction and pain control using an opioid-sparing postoperative pathway. J Am Coll Surg 2019;229:316–22. 10.1016/j.jamcollsurg.2019.04.020
    1. Fullen BM, Baxter GD, O’Donovan BGG, Doody C, Daly L, Hurley DA. Doctors’ attitudes and beliefs regarding acute low back pain management: asystematic review. Pain 2008;136:388–96. 10.1016/j.pain.2008.01.003
    1. Swenson C, Prashar N, Mangino A, Thode HC, Singer AJ. Preference for opioids in emergency department patients with acute musculoskeletal pain. Am J Emerg Med 2019;37:730–2. 10.1016/j.ajem.2018.12.057
    1. Cherkin DC, Deyo RA, Wheeler K, Ciol MA. Physician views about treating low back pain. The results of a national survey. Spine 1995;20:1–10. 10.1097/00007632-199501000-00001
    1. Green CR, Wheeler JRC, LaPorte F. Clinical decision making in pain management: contributions of physician and patient characteristics to variations in practice. J Pain 2003;4:29–39. 10.1054/jpai.2003.5
    1. Mikhail C, Korner-Bitensky N, Rossignol M, Dumas J-P. Physical therapists’ use of interventions with high evidence of effectiveness in the management of a hypothetical typical patient with acute low back pain. Phys Ther 2005;85:1151–67. 10.1093/ptj/85.11.1151
    1. Glassberg JA, Tanabe P, Chow A, et al. Emergency provider analgesic practices and attitudes toward patients with sickle cell disease. Ann Emerg Med 2013;62:293–302.e10. 10.1016/j.annemergmed.2013.02.004
    1. Fullen BM, Baxter GD, O’Donovan BGG, Doody C, Daly LE, Hurley DA. Factors impacting on doctors’ management of acute low back pain: a systematic review. Eur J Pain 2009;13:908–14. 10.1016/j.ejpain.2008.11.013
    1. Adelman JU, Belsey J. Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. J Manag Care Pharm 2003;9:45–52. 10.18553/jmcp.2003.9.1.45
    1. Hansen RN, Oster G, Edelsberg J, Woody GE, Sullivan SD. Economic costs of nonmedical use of prescription opioids. Clin J Pain 2011;27:194–202. 10.1097/AJP.0b013e3181ff04ca
    1. Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011;12:657–67. 10.1111/j.1526-4637.2011.01075.x
    1. Inocencio TJ, Carroll NV, Read EJ, Holdford DA. The economic burden of opioid-related poisoning in the United States. Pain Med 2013;14:1534–47. 10.1111/pme.12183
    1. Stagnitti MN. Trends in prescribed outpatient opioid use and expenses in the U.S. civilian noninstitutionalized population, 2002–2012. Statistical brief #478. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
    1. Gore M, Tai K-S, Sadosky A, Leslie D, Stacey BR. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings. Pain Pract 2012;12:550–60. 10.1111/j.1533-2500.2012.00532.x
    1. Laffer A, Murphy R, Winegarden W, et al. An economic analysis of the costs and benefits associated with regular urine drug testing for chronic pain patients in the United States. Nashville, TN: Laffer Associates; 2011.
    1. Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care 2016;54:901–6. 10.1097/MLR.0000000000000625
    1. Cox C, Rae M, Sawyer B. A look at how the opioid crisis has affected people with employer coverage. Peterson-KFF Health System Tracker; 2018.
    1. Young K. Utilization and spending trends in Medicaid outpatient prescription drugs, 2014–2017. KFF; 2019.
    1. Chen Q, Larochelle MR, Weaver DT, et al. Prevention of prescription opioid misuse and projected overdose deaths in the United States. JAMA Netw Open 2019;2:e187621. 10.1001/jamanetworkopen.2018.7621
    1. Murphy SM, Polsky D. Economic evaluations of opioid use disorder interventions. PharmacoEconomics 2016;34:863–87. 10.1007/s40273-016-0400-5
    1. Kenworthy J, Yi Y, Wright A, Brown J, Maria Madrigal A, Dunlop WCN. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study. J Med Econ 2017;20:740–8. 10.1080/13696998.2017.1325744
    1. Krebs E, Enns B, Evans E, et al. Cost-effectiveness of publicly funded treatment of opioid use disorder in California. Ann Intern Med 2018;168:10–9. 10.7326/M17-0611
    1. Center for Health Information and Analysis. Mandated benefit review of H.B. 3972: an act relative to the practice of acupuncture. Boston, MA: Center for Health Information and Analysis; 2015.
    1. Hurley MV, Walsh NE, Mitchell HL, et al. Economic evaluation of a rehabilitation program integrating exercise, self-management, and active coping strategies for chronic knee pain. Arthritis Rheum 2007;57:1220–9. 10.1002/art.23011
    1. Jessep SA, Walsh NE, Ratcliffe J, Hurley MV. Long-term clinical benefits and costs of an integrated rehabilitation programme compared with outpatient physiotherapy for chronic knee pain. Physiotherapy 2009;95:94–102. 10.1016/j.physio.2009.01.005
    1. Oppong R, Jowett S, Nicholls E, et al. Joint protection and hand exercises for hand osteoarthritis: an economic evaluation comparing methods for the analysis of factorial trials. Rheumatology (Oxford) 2015;54:876–83. 10.1093/rheumatology/keu389
    1. Sevick MA, Bradham DD, Muender M, et al. Cost-effectiveness of aerobic and resistance exercise in seniors with knee osteoarthritis. Med Sci Sports Exerc 2000;32:1534–40. 10.1097/00005768-200009000-00002
    1. Sevick MA, Miller GD, Loeser RF, Williamson JD, Messier SP. Cost-effectiveness of exercise and diet in overweight and obese adults with knee osteoarthritis. Med Sci Sports Exerc 2009;41:1167–74. 10.1249/MSS.0b013e318197ece7
    1. Coupé VMH, Veenhof C, van Tulder MW, Dekker J, Bijlsma JWJ, Van den Ende CHM. The cost effectiveness of behavioural graded activity in patients with osteoarthritis of hip and/or knee. Ann Rheum Dis 2007;66:215–21. 10.1136/ard.2006.054478
    1. MacPherson H, Vickers A, Bland M, et al. Acupuncture for chronic pain and depression in primary care: a programme of research. Programme Grants Appl Res 2017;5:1–316. 10.3310/pgfar05030
    1. Dagenais S, Caro J, Haldeman S. A systematic review of low back pain cost of illness studies in the United States and internationally. Spine J 2008;8:8–20. 10.1016/j.spinee.2007.10.005
    1. Lin C-WC, Haas M, Maher CG, Machado LAC, van Tulder MW. Cost-effectiveness of general practice care for low back pain: a systematic review. Eur Spine J 2011;20:1012–23. 10.1007/s00586-010-1675-4
    1. Andronis L, Kinghorn P, Qiao S, Whitehurst DGT, Durrell S, McLeod H. Cost-effectiveness of non-invasive and non-pharmacological interventions for low back pain: a systematic literature review. Appl Health Econ Health Policy 2017;15:173–201. 10.1007/s40258-016-0268-8
    1. Tsertsvadze A, Clar C, Court R, Clarke A, Mistry H, Sutcliffe P. Cost-effectiveness of manual therapy for the management of musculoskeletal conditions: a systematic review and narrative synthesis of evidence from randomized controlled trials. J Manipulative Physiol Ther 2014;37:343–62. 10.1016/j.jmpt.2014.05.001
    1. Herman PM, Lavelle TA, Sorbero ME, Hurwitz EL, Coulter ID. Are nonpharmacologic interventions for chronic low back pain more cost effective than usual care? Proof of concept results from a Markov model. Spine 2019;44:1456–64. 10.1097/BRS.0000000000003097
    1. Aboagye E, Karlsson ML, Hagberg J, Jensen I. Cost-effectiveness of early interventions for non-specific low back pain: a randomized controlled study investigating medical yoga, exercise therapy and self-care advice. J Rehabil Med 2015;47:167–73. 10.2340/16501977-1910
    1. Haines T, Bowles K-A. Cost-effectiveness of using a motion-sensor biofeedback treatment approach for the management of sub-acute or chronic low back pain: economic evaluation alongside a randomised trial. BMC Musculoskelet Disord 2017;18:18. 10.1186/s12891-016-1371-6
    1. Herman PM, Anderson ML, Sherman KJ, Balderson BH, Turner JA, Cherkin DC. Cost-effectiveness of mindfulness-based stress reduction versus cognitive behavioral therapy or usual care among adults with chronic low back pain. Spine 2017;42:1511–20. 10.1097/BRS.0000000000002344
    1. Suni JH, Kolu P, Tokola K, et al. Effectiveness and cost-effectiveness of neuromuscular exercise and back care counseling in female healthcare workers with recurrent non-specific low back pain: a blinded four-arm randomized controlled trial. BMC Public Health 2018;18:1376. 10.1186/s12889-018-6293-9
    1. Driessen MT, Lin C-WC, van Tulder MW. Cost-effectiveness of conservative treatments for neck pain: a systematic review on economic evaluations. Eur Spine J 2012;21:1441–50. 10.1007/s00586-012-2272-5
    1. Miyamoto GC, Lin CC, Cabral CMN, van Dongen JM, van Tulder MW. Cost-effectiveness of exercise therapy in the treatment of non-specific neck pain and low back pain: a systematic review with meta-analysis. Br J Sports Med 2019;53:172–81. 10.1136/bjsports-2017-098765
    1. van der Velde G, Yu H, Paulden M, et al. Which interventions are cost-effective for the management of whiplash-associated and neck pain-associated disorders? A systematic review of the health economic literature by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration. Spine J 2016;16:1582–97. 10.1016/j.spinee.2015.08.025
    1. Essex H, Parrott S, Atkin K, et al. An economic evaluation of Alexander Technique lessons or acupuncture sessions for patients with chronic neck pain: A randomized trial (ATLAS). PLoS One 2017;12:e0178918. 10.1371/journal.pone.0178918
    1. Willich SN, Reinhold T, Selim D, Jena S, Brinkhaus B, Witt CM. Cost-effectiveness of acupuncture treatment in patients with chronic neck pain. Pain 2006;125:107–13. 10.1016/j.pain.2006.06.006
    1. Robinson RL, Jones ML. In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review. Expert Opin Pharmacother 2006;7:1027–39. 10.1517/14656566.7.8.1027
    1. Luciano JV, D’Amico F, Cerdà-Lafont M, et al. Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial. Arthritis Res Ther 2014;16:451. 10.1186/s13075-014-0451-y
    1. Hsiao B, Fraenkel L. Patient preferences for rheumatoid arthritis treatment. Curr Opin Rheumatol 2019;31:256–63. 10.1097/BOR.0000000000000591
    1. Wielage R, Bansal M, Wilson K, Klein R, Happich M. Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective. Spine 2013;38:936–46. 10.1097/BRS.0b013e31828264f9
    1. Huelin R, Pokora T, Foster TS, Mould JF. Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies. Expert Rev Pharmacoecon Outcomes Res 2012;12:505–23. 10.1586/erp.12.36
    1. Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW. Duloxetine use in chronic low back pain: treatment patterns and costs. PharmacoEconomics 2012;30:595–609. 10.2165/11598130-000000000-00000
    1. Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW. Duloxetine use in employees with low back pain: treatment patterns and direct and indirect costs. Pain Med 2014;15:1015–26. 10.1111/pme.12362
    1. Morera-Domínguez C, Ceberio-Balda F, Flórez-García M, Masramón X, López-Gómez V. A cost-consequence analysis of pregabalin versus usual care in the symptomatic treatment of refractory low back pain: sub-analysis of observational trial data from orthopaedic surgery and rehabilitation clinics. Clin Drug Investig 2010;30:517–31. 10.2165/11536280-000000000-00000
    1. O’Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. PharmacoEconomics 2009;27:95–112. 10.2165/00019053-200927020-00002
    1. Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. J Pain 2006;7:119–28. 10.1016/j.jpain.2005.09.004
    1. Wu EQ, Birnbaum HG, Mareva MN, et al. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain 2006;7:399–407. 10.1016/j.jpain.2006.01.443
    1. Wu N, Chen S, Boulanger L, Rao P, Zhao Y. Average daily dose, medication adherence, and healthcare costs among commercially-insured patients with fibromyalgia treated with duloxetine. Curr Med Res Opin 2011;27:1131–9. 10.1185/03007995.2011.570744
    1. Zhao Y, Wu N, Chen S, Boulanger L, Police RL, Fraser K. Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies. Curr Med Res Opin 2010;26:2147–56. 10.1185/03007995.2010.503140
    1. Darbà J, Kaskens L, Pérez C, Álvarez E, Navarro-Artieda R, Sicras-Mainar A. Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective. Adv Ther 2014;31:1–29. 10.1007/s12325-013-0088-2
    1. Parker L, Huelin R, Khankhel Z, Wasiak R, Mould J. A systematic review of pharmacoeconomic studies for pregabalin. Pain Pract 2015;15:82–94. 10.1111/papr.12193
    1. Tarride J-E, Gordon A, Vera-Llonch M, Dukes E, Rousseau C. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther 2006;28:1922–34. 10.1016/j.clinthera.2006.11.017
    1. de Salas-Cansado M, Pérez C, Saldaña MT, Navarro A, Rejas J. A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain. Pain Med 2012;13:699–710. 10.1111/j.1526-4637.2012.01375.x
    1. Gordon J, Lister S, Prettyjohns M, McEwan P, Tetlow A, Gabriel Z. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain. J Med Econ 2012;15:207–18. 10.3111/13696998.2011.632797
    1. Armstrong EP, Malone DC, McCarberg B, Panarites CJ, Pham SV. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. Curr Med Res Opin 2011;27:939–50. 10.1185/03007995.2011.562885
    1. Mankowski C, Patel S, Trueman D, Bentley A, Poole C. Cost-effectiveness of capsaicin 8% patch compared with pregabalin for the treatment of patients with peripheral neuropathic pain in Scotland. PLoS One 2016;11:e0150973. 10.1371/journal.pone.0150973
    1. Liedgens H, Hertel N, Gabriel A, et al. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective. Clin Drug Investig 2008;28:583–601. 10.2165/00044011-200828090-00005
    1. Kirson NY, Ivanova JI, Birnbaum HG, et al. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. J Med Econ 2010;13:482–91. 10.3111/13696998.2010.506176
    1. Beard SM, Roskell N, Le TK, et al. Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States. J Med Econ 2011;14:463–76. 10.3111/13696998.2011.586389
    1. Burke JP, Sanchez RJ, Joshi AV, Cappelleri JC, Kulakodlu M, Halpern R. Health care costs in patients with fibromyalgia on pregabalin vs. duloxetine. Pain Pract 2012;12:14–22. 10.1111/j.1533-2500.2011.00470.x
    1. Gore M, Tai K-S, Chandran A, Zlateva G, Leslie D. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care. J Med Econ 2012;15:19–31. 10.3111/13696998.2011.629262
    1. Harnett J, Margolis J, Cao Z, et al. Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine. Pain Pract 2011;11:217–29. 10.1111/j.1533-2500.2010.00440.x
    1. Kleinman NL, Sanchez RJ, Lynch WD, Cappelleri JC, Beren IA, Joshi AV. Health outcomes and costs among employees with fibromyalgia treated with pregabalin vs. standard of care. Pain Pract 2011;11:540–51. 10.1111/j.1533-2500.2011.00453.x
    1. Lloyd A, Boomershine CS, Choy EH, Chandran A, Zlateva G. The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective. J Med Econ 2012;15:481–92. 10.3111/13696998.2012.660254
    1. Sun P, Peng X, Sun S, et al. Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators. Pain Pract 2014;14:22–31. 10.1111/papr.12044
    1. Zhao Y, Sun P, Watson P. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin. Curr Med Res Opin 2011;27:785–92. 10.1185/03007995.2011.554807
    1. Gan TJ, Lubarsky DA, Flood EM, et al. Patient preferences for acute pain treatment. Br J Anaesth 2004;92:681–8. 10.1093/bja/aeh123
    1. Rogerson MD, Gatchel RJ, Bierner SM. A cost utility analysis of interdisciplinary early intervention versus treatment as usual for high-risk acute low back pain patients. Pain Pract 2010;10:382–95. 10.1111/j.1533-2500.2009.00344.x
    1. Seferlis T, Lindholm L, Németh G. Cost-minimisation analysis of three conservative treatment programmes in 180 patients sick-listed for acute low-back pain. Scand J Prim Health Care 2000;18:53–7. 10.1080/02813430050202578
    1. Lin CC, Li Q, Williams CM, et al. The economic burden of guideline-recommended first line care for acute low back pain. Eur Spine J 2018;27:109–16. 10.1007/s00586-016-4781-0
    1. Walker J, Mertens UK, Schmidt CO, Chenot J-F. Effect on healthcare utilization and costs of spinal manual therapy for acute low back pain in routine care: a propensity score matched cohort study. PLoS One 2017;12:e0177255. 10.1371/journal.pone.0177255
    1. Gold LS, Strassels SA, Hansen RN. Health care costs and utilization in patients receiving prescriptions for long-acting opioids for acute postsurgical pain. Clin J Pain 2016;32:747–54. 10.1097/AJP.0000000000000322
    1. Asseburg C, Peura P, Oksanen T, Turunen J, Purmonen T, Martikainen J. Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison. Int J Technol Assess Health Care 2012;28:382–9. 10.1017/S0266462312000517
    1. Belsey JD. Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials. Curr Med Res Opin 2004;20:659–69. 10.1185/030079904125003403
    1. Cady RK, Sheftell F, Lipton RB, Kwong WJ, O’Quinn S. Economic implications of early treatment of migraine with sumatriptan tablets. Clin Ther 2001;23:284–91. 10.1016/S0149-2918(01)80011-4
    1. Kelman L, Von Seggern RL. Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy. Am J Ther 2006;13:411–7. 10.1097/01.mjt.0000174354.05142.c1
    1. Lofland JH, Kim SS, Batenhorst AS, et al. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc 2001;76:1093–101. 10.4065/76.11.1093
    1. Lofland JH, Nash DB. Oral serotonin receptor agonists: a review of their cost effectiveness in migraine. PharmacoEconomics 2005;23:259–74. 10.2165/00019053-200523030-00006
    1. Mullins CD, Subedi PR, Healey PJ, Sanchez RJ. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective. Pharmacotherapy 2007;27:1092–101. 10.1592/phco.27.8.1092
    1. Perfetto EM, Weis KA, Mullins CD, Subedi P, Healey PJ Sr. An economic evaluation of triptan products for migraine. Value Health 2005;8:647–55. 10.1111/j.1524-4733.2005.00056.x
    1. Williams P, Reeder CE. A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J Manag Care Pharm 2004;10:259–65. 10.18553/jmcp.2004.10.3.259
    1. Zhang L, Hay JW. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine. CNS Drugs 2005;19:635–42. 10.2165/00023210-200519070-00005
    1. Chou R, Selph S, Wagner J, et al. Systematic review on opioid treatments for chronic pain: surveillance report 3. AHRQ publication no. 22-EHC032. Rockville, MD: Agency for Healthcare Research and Quality; June 2022.
    1. Markman JD, Bolash RB, McAlindon TE, et al. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety. Pain 2020;161:2068–78. 10.1097/j.pain.0000000000001928
    1. Spierings ELH, Fidelholtz J, Wolfram G, Smith MD, Brown MT, West CR. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain 2013;154:1603–12. 10.1016/j.pain.2013.04.035
    1. van de Donk T, van Cosburgh J, van Dasselaar T, et al. Tapentadol treatment results in long-term pain relief in patients with chronic low back pain and associates with reduced segmental sensitization. Pain Rep 2020;5:e877. 10.1097/PR9.0000000000000877
    1. Maheu E, Soriot-Thomas S, Noel E, Ganry H, Lespessailles E, Cortet B. Wearable transcutaneous electrical nerve stimulation (actiTENS®) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trial versus weak opioids. Ther Adv Musculoskelet Dis 2022;14:1759720X211066233. 10.1177/1759720X211066233
    1. Agnoli A, Xing G, Tancredi DJ, Magnan E, Jerant A, Fenton JJ. Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids. JAMA 2021;326:411–9. 10.1001/jama.2021.11013
    1. Hallvik SE, El Ibrahimi S, Johnston K, et al. Patient outcomes after opioid dose reduction among patients with chronic opioid therapy. Pain 2022;163:83–90. 10.1097/j.pain.0000000000002298
    1. Selph S, McDonagh M, Pappas M, et al. Systematic review on nonopioid pharmacologic treatments for chronic pain: surveillance report 3. AHRQ publication no. 22-EHC034 Rockville, MD: Agency for Healthcare Research and Quality; June 2022.
    1. Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 2013;260:984–97. 10.1007/s00415-012-6739-4
    1. Khasbage S, Shukla R, Sharma P, Singh S. A randomized control trial of duloxetine and gabapentin in painful diabetic neuropathy. J Diabetes 2021;13:532–41. 10.1111/1753-0407.13148
    1. Shahid W, Kumar R, Shaikh A, Kumar S, Jameel R, Fareed S. Comparison of the efficacy of duloxetine and pregabalin in pain relief associated with diabetic neuropathy. Cureus 2019;11:e5293. 10.7759/cureus.5293
    1. Hussain N, Said ASA, Javaid FA, et al. The efficacy and safety profile of capsaicin 8% patch versus 5% Lidocaine patch in patients with diabetic peripheral neuropathic pain: a randomized, placebo-controlled study of south Asian male patients. J Diabetes Metab Disord 2021;20:271–8. 10.1007/s40200-021-00741-2
    1. Skelly A, Brodt E, Kantner S, Diulio-Nakamura A, Mauer K, Shetty K. Systematic review on noninvasive nonpharmacological treatment for chronic pain: surveillance report 3. AHRQ publication no. 22-EHC035. Rockville, MD: Agency for Healthcare Research and Quality; June 2022.
    1. Xiao Z, Li G. The effect of Wuqinxi exercises on the balance function and subjective quality of life in elderly, female knee osteoarthritis patients. Am J Transl Res 2021;13:6710–6.
    1. Alqualo-Costa R, Rampazo ÉP, Thome GR, Perracini MR, Liebano RE. Interferential current and photobiomodulation in knee osteoarthritis: a randomized, placebo-controlled, double-blind clinical trial. Clin Rehabil 2021;35:1413–27. 10.1177/02692155211012004
    1. Chou R, Griffin J, Blazina I, Schwarz E, Atchison C, Mauer K. Systematic review on treatments for acute pain: surveillance report 3. AHRQ publication no. 22-EHC022. Rockville, MD: Agency for Healthcare Research and Quality; June 2022.
    1. Ilyas AM, Chapman T, Zmistowski B, Sandrowski K, Graham J, Hammoud S. The effect of preoperative opioid education on opioid consumption after outpatient orthopedic surgery: a prospective randomized trial. Orthopedics 2021;44:123–7. 10.3928/01477447-20210201-07
    1. Paskey T, Vincent S, Critchlow E, et al. Prospective randomized study evaluating the effects of preoperative opioid counseling on postoperative opioid use after outpatient lower extremity orthopaedic surgery. J Surg Orthop Adv 2021;30:2–6.
    1. Zhu CY, Schumm MA, Hu TX, et al. Patient-centered decision-making for postoperative narcotic-free endocrine surgery: a randomized clinical trial. JAMA Surg 2021;156:e214287. 10.1001/jamasurg.2021.4287
    1. VanderPluym JH, Halker Singh RB, Farah MH, et al. Acute treatments for episodic migraine: surveillance report 3. AHRQ publication no. 22-EHC041. Rockville, MD: Agency for Healthcare Research and Quality; August 2022.
    1. Winner PK, McAllister P, Chakhava G, et al. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA 2021;325:2348–56. 10.1001/jama.2021.7665
    1. Meek R, Graudins A, McDonald M, McGannon D, Limm E. Comparing propofol with placebo for early resolution of acute migraine in adult emergency department patients: a double-blind randomized controlled trial. Emerg Med Australas 2021;33:465–72. 10.1111/1742-6723.13659
    1. Friedman BW, Irizarry E, Williams A, et al. A randomized, double-dummy, emergency department-based study of greater occipital nerve block with bupivacaine vs intravenous metoclopramide for treatment of migraine. Headache 2020;60:2380–8. 10.1111/head.13961
    1. Hokenek NM, Ozer D, Yılmaz E, et al. Comparison of greater occipital nerve and supra orbital nerve blocks methods in the treatment of acute migraine attack: a randomized double-blind controlled trial. Clin Neurol Neurosurg 2021;207:106821. 10.1016/j.clineuro.2021.106821
    1. Antal A, Bischoff R, Stephani C, et al. Low intensity, transcranial, alternating current stimulation reduces migraine attack burden in a home application set-up: a double-blinded, randomized feasibility study. Brain Sci 2020;10:888. 10.3390/brainsci10110888
    1. Shah R, Assis F, Narasimhan B, et al.. Trans-nasal high-flow dehumidified air in acute migraine headaches: a randomized controlled trial. Cephalalgia 2021;41:968–78. 10.1177/0333102421997766
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington, DC: American Psychiatric Association; 2000.
    1. Compton WM, Dawson DA, Goldstein RB, Grant BF. Crosswalk between DSM-IV dependence and DSM-5 substance use disorders for opioids, cannabis, cocaine and alcohol. Drug Alcohol Depend 2013;132:387–90. 10.1016/j.drugalcdep.2013.02.036
    1. Kelly JF, Saitz R, Wakeman S. Language, substance use disorders, and policy: the need to reach consensus on an “Addiction-ary.” Alcohol Treat Q 2016;34:116–23. 10.1080/07347324.2016.1113103
    1. Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. Int J Drug Policy 2010;21:202–7.10.1016/j.drugpo.2009.10.010
    1. National Institute on Drug Abuse. Words matter: preferred language for talking about addiction. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse; 2021.
    1. Schappert SM, Burt CW. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001–02. Vital Health Stat 13 2006;(159):1–66.
    1. Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: National Academies Press; 2011.
    1. Tighe P, Buckenmaier CC 3rd, Boezaart AP, et al. Acute pain medicine in the United States: a status report. Pain Med 2015;16:1806–26. 10.1111/pme.12760
    1. Banerjee S, Argáez C. Multidisciplinary treatment programs for patients with acute or subacute pain: a review of clinical effectiveness, cost-effectiveness, and guidelines [Internet]. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2019. May 7.
    1. Zelaya CE, Dahlhamer JM, Lucas JW, Connor EM. Chronic pain and high-impact chronic pain among U.S. adults, 2019. NCHS Data Brief 2020;390:1–8.
    1. US Department of Health and Human Services. Pain management best practices inter-agency task force report: updates, gaps, inconsistencies, and recommendations. Washington, DC: US Department of Health and Human Services; 2019.
    1. Chou R, Hartung D, Turner J, et al. Opioid treatments for chronic pain. Comparative effectiveness review no. 229. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
    1. McDonagh M, Selph S, Buckley D, et al. Nonopioid pharmacologic treatments for chronic pain. Comparative effectiveness review no. 228. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
    1. Skelly A, Chou R, Dettori J, et al. Noninvasive nonpharmacological treatment for chronic pain: a systematic review update. Comparative effectiveness review no. 227. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
    1. Chou R, Wagner J, Ahmed A, et al. Treatments for acute pain: a systematic review. Comparative effectiveness review no. 240. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
    1. Halker Singh R, VanderPluym J, Morrow A, et al. Acute treatments for episodic migraine. Comparative effectiveness review no. 239. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
    1. Hooten WM. Chronic pain and mental health disorders: shared neural mechanisms, epidemiology, and treatment. Mayo Clin Proc 2016;91:955–70. 10.1016/j.mayocp.2016.04.029
    1. Morasco BJ, Gritzner S, Lewis L, Oldham R, Turk DC, Dobscha SK. Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder. Pain 2011;152:488–97. 10.1016/j.pain.2010.10.009
    1. Smith MT, Edwards RR, Robinson RC, Dworkin RH. Suicidal ideation, plans, and attempts in chronic pain patients: factors associated with increased risk. Pain 2004;111:201–8. 10.1016/j.pain.2004.06.016
    1. Racine M. Chronic pain and suicide risk: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2018;87(Pt B):269–80. 10.1016/j.pnpbp.2017.08.020
    1. Petrosky E, Harpaz R, Fowler KA, et al. Chronic pain among suicide decedents, 2003 to 2014: findings from the National Violent Death Reporting System. Ann Intern Med 2018;169:448–55. 10.7326/M18-0830
    1. Becker WC, Dorflinger L, Edmond SN, Islam L, Heapy AA, Fraenkel L. Barriers and facilitators to use of non-pharmacological treatments in chronic pain. BMC Fam Pract 2017;18:41. 10.1186/s12875-017-0608-2
    1. Bazargan M, Yazdanshenas H, Gordon D, Orum G. Pain in community-dwelling elderly African Americans. J Aging Health 2016;28:403–25. 10.1177/0898264315592600
    1. Evans MC, Bazargan M, Cobb S, Assari S. Pain intensity among community-dwelling African American older adults in an economically disadvantaged area of Los Angeles: social, behavioral, and health determinants. Int J Environ Res Public Health 2019;16:20. 10.3390/ijerph16203894
    1. Rupp T, Delaney KA. Inadequate analgesia in emergency medicine. Ann Emerg Med 2004;43:494–503. 10.1016/j.annemergmed.2003.11.019
    1. Simon R, Snow R, Wakeman S. Understanding why patients with substance use disorders leave the hospital against medical advice: a qualitative study. Subst Abus 2020;41:519–25. 10.1080/08897077.2019.1671942
    1. Yazdanshenas H, Bazargan M, Smith J, Martins D, Motahari H, Orum G. Pain treatment of underserved older African Americans. J Am Geriatr Soc 2016;64:2116–21. 10.1111/jgs.14302
    1. Phillips S, Chen Y, Masese R, et al. Perspectives of individuals with sickle cell disease on barriers to care. PLoS One 2022;17:e0265342. 10.1371/journal.pone.0265342
    1. Morden NE, Chyn D, Wood A, Meara E. Racial inequality in prescription opioid receipt—role of individual health systems. N Engl J Med 2021;385:342–51. 10.1056/NEJMsa2034159
    1. Ly DP. Racial and ethnic disparities in the evaluation and management of pain in the outpatient setting, 2006–2015. Pain Med 2019;20:223–32. 10.1093/pm/pny074
    1. Joynt M, Train MK, Robbins BW, Halterman JS, Caiola E, Fortuna RJ. The impact of neighborhood socioeconomic status and race on the prescribing of opioids in emergency departments throughout the United States. J Gen Intern Med 2013;28:1604–10. 10.1007/s11606-013-2516-z
    1. Johnson JD, Asiodu IV, McKenzie CP, et al. Racial and ethnic inequities in postpartum pain evaluation and management. Obstet Gynecol 2019;134:1155–62. 10.1097/AOG.0000000000003505
    1. Goyal MK, Kuppermann N, Cleary SD, Teach SJ, Chamberlain JM. Racial disparities in pain management of children with appendicitis in emergency departments. JAMA Pediatr 2015;169:996–1002. 10.1001/jamapediatrics.2015.1915
    1. Lee P, Le Saux M, Siegel R, et al. Racial and ethnic disparities in the management of acute pain in US emergency departments: meta-analysis and systematic review. Am J Emerg Med 2019;37:1770–7. 10.1016/j.ajem.2019.06.014
    1. Hausmann LRM, Gao S, Lee ES, Kwoh KC. Racial disparities in the monitoring of patients on chronic opioid therapy. Pain 2013;154:46–52. 10.1016/j.pain.2012.07.034
    1. Majedi H, Dehghani SS, Soleyman-Jahi S, et al. Assessment of factors predicting inadequate pain management in chronic pain patients. Anesth Pain Med 2019;9:e97229. 10.5812/aapm.97229
    1. Schieber LZ, Guy GP Jr, Seth P, Losby JL. Variation in adult outpatient opioid prescription dispensing by age and sex—United States, 2008–2018. MMWR Morb Mortal Wkly Rep 2020;69:298–302. 10.15585/mmwr.mm6911a5
    1. Prunuske JP, St Hill CA, Hager KD, et al. Opioid prescribing patterns for non-malignant chronic pain for rural versus non-rural US adults: a population-based study using 2010 NAMCS data. BMC Health Serv Res 2014;14:563. 10.1186/s12913-014-0563-8
    1. Wilson N, Kariisa M, Seth P, Smith H 4th, Davis NL. Drug and opioid-involved overdose deaths—United States, 2017–2018. MMWR Morb Mortal Wkly Rep 2020;69:290–7. 10.15585/mmwr.mm6911a4
    1. Becker WC, Starrels JL, Heo M, Li X, Weiner MG, Turner BJ. Racial differences in primary care opioid risk reduction strategies. Ann Fam Med 2011;9:219–25. 10.1370/afm.1242
    1. Gaither JR, Gordon K, Crystal S, et al. Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients. Drug Alcohol Depend 2018;192:371–6. 10.1016/j.drugalcdep.2018.05.033
    1. Soares WE 3rd, Knowles KJ 2nd, Friedmann PD. A thousand cuts: racial and ethnic disparities in emergency medicine. Med Care 2019;57:921–3. 10.1097/MLR.0000000000001250
    1. Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA 2008;299:70–8. 10.1001/jama.2007.64
    1. Ghoshal M, Shapiro H, Todd K, Schatman ME. Chronic noncancer pain management and systemic racism: time to move toward equal care standards. J Pain Res 2020;13:2825–36. 10.2147/JPR.S287314
    1. Nelson SC, Hackman HW. Race matters: perceptions of race and racism in a sickle cell center. Pediatr Blood Cancer 2013;60:451–4. 10.1002/pbc.24361
    1. Jamison RN, Sheehan KA, Scanlan E, Matthews M, Ross EL. Beliefs and attitudes about opioid prescribing and chronic pain management: survey of primary care providers. J Opioid Manag 2014;10:375–82. 10.5055/jom.2014.0234
    1. Lin DH, Jones CM, Compton WM, et al. Prescription drug coverage for treatment of low back pain among US Medicaid, Medicare Advantage, and commercial insurers. JAMA Netw Open 2018;1:e180235. 10.1001/jamanetworkopen.2018.0235
    1. Heyward J, Jones CM, Compton WM, et al. Coverage of nonpharmacologic treatments for low back pain among US public and private insurers. JAMA Netw Open 2018;1:e183044. 10.1001/jamanetworkopen.2018.3044
    1. Benzing AC, Bell C, Derazin M, Mack R, MacIntosh T. Disparities in opioid pain management for long bone fractures. J Racial Ethn Health Disparities 2020;7:740–5. 10.1007/s40615-020-00701-1
    1. Saluja B, Bryant Z. How implicit bias contributes to racial disparities in maternal morbidity and mortality in the United States. J Womens Health (Larchmt) 2021;30:270–3. 10.1089/jwh.2020.8874
    1. Sabin JA, Greenwald AG. The influence of implicit bias on treatment recommendations for 4 common pediatric conditions: pain, urinary tract infection, attention deficit hyperactivity disorder, and asthma. Am J Public Health 2012;102:988–95. 10.2105/AJPH.2011.300621
    1. Chou R, Deyo R, Devine B, et al. The effectiveness and risks of long-term opioid treatment of chronic pain. Evidence report/technology assessment no. 218. AHRQ publication no. 14–E005-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
    1. Dahlhamer JM, Connor EM, Bose J, Lucas JL, Zelaya CE. Prescription opioid use among adults with chronic pain: United States, 2019. Natl Health Stat Rep 2021;162:1–9. 10.15620/cdc:107641
    1. Food and Drug Administration. Letter to application holders: ER/LA opioid analgesic class labeling changes and postmarket requirements. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration.
    1. Food and Drug Administration. FDA announces enhanced warnings for immediate-release opioid pain medications related to risks of misuse, abuse, addiction, overdose and death. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2016.
    1. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2021.
    1. Paulozzi L, Jones C, Mack K, Rudd R; CDC. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep 2011;60:1487–92.
    1. Han B, Compton WM, Jones CM, Cai R. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003–2013. JAMA 2015;314:1468–78. 10.1001/jama.2015.11859
    1. Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain 2014;30:557–64. 10.1097/AJP.0000000000000021
    1. Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011;305:1315–21. 10.1001/jama.2011.370
    1. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep 2016;65(No. RR-1):1–49. 10.15585/mmwr.rr6501e1
    1. CDC. CDC’s clinical practice guideline for prescribing opioids for pain. Atlanta, GA: US Department of Health and Human Services, CDC; 2022.
    1. Bohnert ASB, Guy GP Jr, Losby JL. Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention’s 2016 opioid guideline. Ann Intern Med 2018;169:367–75. 10.7326/M18-1243
    1. Salvatore PP, Guy GP Jr, Mikosz CA. Changes in opioid dispensing by medical specialties after the release of the 2016 CDC guideline for prescribing opioids for chronic pain. Pain Med 2022;pnac068. 10.1093/pm/pnac068
    1. Goldstick JE, Guy GP, Losby JL, Baldwin GT, Myers MG, Bohnert ASB. Patterns in nonopioid pain medication prescribing after the release of the 2016 guideline for prescribing opioids for chronic pain. JAMA Netw Open 2022;5:e2216475. 10.1001/jamanetworkopen.2022.16475
    1. Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018. 115th Congress. Pub. L. No. 115–271, Sect. 1010. US Government Publishing Office; 2018.
    1. Centers for Medicare & Medicaid Services. Medicaid strategies for non-opioid pharmacologic and non-pharmacologic chronic pain management. CMCS Informational Bulletin. Baltimore, MD: US Department of Health and Human Services, Centers for Medicare & Medicaid Services; 2019.
    1. National Conference of State Legislatures. Prescribing policies: states confront opioid overdose epidemic. Washington, DC: National Conference of State Legislatures; 2019.
    1. US Department of Health and Human Services. Substance use disorder prevention that promotes opioid recovery and treatment for patients and communities (SUPPORT) Act section 7024: report to congress on opioid prescribing limits. Washington, DC: US Department of Health and Human Services; 2020.
    1. Haffajee RL, Cherney S, Smart R. Legal requirements and recommendations to prescribe naloxone. Drug Alcohol Depend 2020;209:107896. 10.1016/j.drugalcdep.2020.107896
    1. Kroenke K, Alford DP, Argoff C, et al. Challenges with implementing the Centers for Disease Control and Prevention opioid guideline: a consensus panel report. Pain Med 2019;20:724–35. 10.1093/pm/pny307
    1. Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid prescribing. N Engl J Med 2019;380:2285–7. 10.1056/NEJMp1904190
    1. Food and Drug Administration. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2019.
    1. Demidenko MI, Dobscha SK, Morasco BJ, Meath THA, Ilgen MA, Lovejoy TI. Suicidal ideation and suicidal self-directed violence following clinician-initiated prescription opioid discontinuation among long-term opioid users. Gen Hosp Psychiatry 2017;47:29–35. 10.1016/j.genhosppsych.2017.04.011
    1. Coffin PO, Rowe C, Oman N, et al. Illicit opioid use following changes in opioids prescribed for chronic non-cancer pain. PLoS One 2020;15:e0232538. 10.1371/journal.pone.0232538
    1. Mark TL, Parish W. Opioid medication discontinuation and risk of adverse opioid-related health care events. J Subst Abuse Treat 2019;103:58–63. 10.1016/j.jsat.2019.05.001
    1. Gordon KS, Manhapra A, Crystal S, et al. All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factors. Drug Alcohol Depend 2020;216:108291. 10.1016/j.drugalcdep.2020.108291
    1. James JR, Scott JM, Klein JW, et al. Mortality after discontinuation of primary care-based chronic opioid therapy for pain: a retrospective cohort study. J Gen Intern Med 2019;34:2749–55. 10.1007/s11606-019-05301-2
    1. Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical trial. JAMA 2018;319:872–82. 10.1001/jama.2018.0899
    1. Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use—United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:265–9. 10.15585/mmwr.mm6610a1
    1. Deyo RA, Hallvik SE, Hildebran C, et al. Association between initial opioid prescribing patterns and subsequent long-term use among opioid-naïve patients: a statewide retrospective cohort study. J Gen Intern Med 2017;32:21–7. 10.1007/s11606-016-3810-3
    1. Hill MV, McMahon ML, Stucke RS, Barth RJ Jr. Wide variation and excessive dosage of opioid prescriptions for common general surgical procedures. Ann Surg 2017;265:709–14. 10.1097/SLA.0000000000001993
    1. Hill MV, Stucke RS, McMahon ML, Beeman JL, Barth RJ Jr. An educational intervention decreases opioid prescribing after general surgical operations. Ann Surg 2018;267:468–72. 10.1097/SLA.0000000000002198
    1. Howard R, Waljee J, Brummett C, Englesbe M, Lee J. Reduction in opioid prescribing through evidence-based prescribing guidelines. JAMA Surg 2018;153:285–7. 10.1001/jamasurg.2017.4436
    1. Hales CM, Martin CB, Gu Q. Prevalence of prescription pain medication use among adults: United States, 2015–2018. NCHS Data Brief 2020;369:1–8.
    1. CDC. U.S. state opioid dispensing rates, 2020. Atlanta, GA: US Department for Health and Human Services, CDC; 2021.
    1. Schieber LZ, Guy GP Jr, Seth P, et al. Trends and patterns of geographic variation in opioid prescribing practices by state, United States, 2006–2017. JAMA Netw Open 2019;2:e190665. 10.1001/jamanetworkopen.2019.0665
    1. Guy GP Jr, Zhang K. Opioid prescribing by specialty and volume in the U.S. Am J Prev Med 2018;55:e153–5. 10.1016/j.amepre.2018.06.008
    1. Mikosz CA, Zhang K, Haegerich T, et al. Indication-specific opioid prescribing for US patients with Medicaid or private insurance, 2017. JAMA Netw Open 2020;3:e204514. 10.1001/jamanetworkopen.2020.4514
    1. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2020.
    1. National Academies of Sciences, Engineering, and Medicine. Framing opioid prescribing guidelines for acute pain: developing the evidence. Washington, DC: National Academies Press; 2019.
    1. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv 2020;4:2656–701. 10.1182/bloodadvances.2020001851
    1. Michigan Opioid Prescribing Engagement Network. Opioid prescribing recommendations: pediatric prescribing recommendations. Ann Arbor, MI: Michigan Opioid Prescribing Engagement Network.
    1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: adolescent and young adult (AYA) oncology, version 1.2023. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2023.
    1. Swarm RA, Paice JA, Anghelescu DL, et al.; BCPS. Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019;17:977–1007. 10.6004/jnccn.2019.0038
    1. Tevaarwerk A, Denlinger CS, Sanft T, et al. Survivorship, version 1.2021. J Natl Compr Canc Netw 2021;19:676–85. 10.6004/jnccn.2021.0028
    1. Paice JA, Portenoy R, Lacchetti C, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2016;34:3325–45. 10.1200/JCO.2016.68.5206
    1. National Consensus Project for Quality Palliative Care. Clinical practice guidelines for quality palliative care, 4th ed. Richmond, VA: National Coalition for Hospice and Palliative Care; 2018.
    1. Committee on Approaching Death: Addressing Key End of Life Issues: Institute of Medicine. Dying in America: improving quality and honoring individual preferences near the end of life. Washington, DC: National Academies Press; 2015.
    1. Schatz AA, Oliver TK, Swarm RA, et al. Bridging the gap among clinical practice guidelines for pain management in cancer and sickle cell disease. J Natl Compr Canc Netw 2020;18:392–9. 10.6004/jnccn.2019.7379
    1. American Society of Addiction Medicine. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med 2020;14(Suppl 1):1–91. 10.1097/ADM.0000000000000633
    1. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015;162:276–86. 10.7326/M14-2559
    1. Contextual evidence review for the CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. Atlanta, GA: US Department of Health and Human Services, CDC; 2016. 10.23970/AHRQEPCSURVEILLANCEOPIOIDCHRONIC
    1. Berkman ND, Lohr KN, Ansari MT, et al. Grading the strength of a body of evidence when assessing health care interventions: an EPC update. J Clin Epidemiol 2015;68:1312–24. 10.1016/j.jclinepi.2014.11.023
    1. Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ; ACIP Evidence Based Recommendations Work Group (EBRWG). Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). Vaccine 2011;29:9171–6. 10.1016/j.vaccine.2011.08.005
    1. Lee G, Carr W, Reingold A, et al.; ACIP Evidence-Based Recommendations Work Group; ACIP Evidence Based Recommendations Work Group. Updated framework for development of evidence-based recommendations by the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2018;67:1271–2. 10.15585/mmwr.mm6745a4
    1. Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6. 10.1136/
    1. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401–6. 10.1016/j.jclinepi.2010.07.015
    1. Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol 2013;66:726–35. 10.1016/j.jclinepi.2013.02.003
    1. Welch VA, Akl EA, Guyatt G, et al. GRADE equity guidelines 1: considering health equity in GRADE guideline development: introduction and rationale. J Clin Epidemiol 2017;90:59–67. 10.1016/j.jclinepi.2017.01.014
    1. Ahmed F. Advisory Committee on Immunization Practices handbook for developing evidence-based recommendations. Version 1.2. Atlanta, GA: US Department of Health and Human Services, CDC; 2013.
    1. CDC. Board of Scientific Counselors: 2019 Opioid Workgroup. Atlanta, GA: US Department of Health and Human Services, CDC; 2021.
    1. CDC. Opioid Workgroup of the National Center for Injury Prevention and Control Board of Scientific Counselors roster. Atlanta, GA: US Department of Health and Human Services, CDC; 2020.
    1. CDC. Opioid Workgroup of the Board of Scientific Counselors of the National Center for Injury Prevention and Control, CDC terms of reference. Atlanta, GA: US Department of Health and Human Services, CDC; 2020.
    1. CDC. Federal advisory committee management handbook. Atlanta, GA: US Department of Health and Human Services, CDC, Management Analysis and Services Office; 2008.
    1. BSC/NCIPC Opioid Workgroup Members. Observations of the Opioid Workgroup of the Board of Scientific Counselors of the National Center for Injury Prevention and Control on the updated CDC guideline for prescribing opioids; 2021.
    1. CDC. Draft CDC clinical practice guideline for prescribing opioids—United States, 2022: Board of Scientific Counselors of the National Center for Injury Prevention and Control’s Opioid Workgroup report and CDC response. Atlanta, GA: US Department of Health and Human Services, CDC; 2022.
    1. CDC. Draft CDC clinical practice guideline for prescribing opioids—United States, 2022: overview of community engagement and public comment opportunities. Atlanta, GA: US Department of Health and Human Services, CDC; 2022.
    1. CDC. NCIPC peer review agenda. Atlanta, GA: US Department of Health and Human Services, CDC; 2022.
    1. CDC. CDC/ATSDR peer review agenda. Atlanta, GA: US Department of Health and Human Services, CDC; 2022.
    1. CDC. Advisory Committee on Immunization Practices (ACIP): evidence-based recommendations—GRADE. Atlanta, GA: US Department of Health and Human Services, CDC; 2018.
    1. US Department of Health and Human Services, Office of Minority Health. Behavioral health implementation guide for the national standards for culturally and linguistically appropriate services in health and health care. Rockville, MD: US Department of Health and Human Services, Office of Minority Health; 2021.
    1. Doherty C, Bleakley C, Delahunt E, Holden S. Treatment and prevention of acute and recurrent ankle sprain: an overview of systematic reviews with meta-analysis. Br J Sports Med 2017;51:113–25. 10.1136/bjsports-2016-096178
    1. Qaseem A, Wilt TJ, McLean RM, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2017;166:514–30. 10.7326/M16-2367
    1. Qaseem A, McLean RM, O’Gurek D, Batur P, Lin K, Kansagara DL; Clinical Guidelines Committee of the American College of Physicians; Commission on Health of the Public and Science of the American Academy of Family Physicians. Nonpharmacologic and pharmacologic management of acute pain from non-low back, musculoskeletal injuries in adults: a clinical guideline from the American College of Physicians and American Academy of Family Physicians. Ann Intern Med 2020;173:739–48. 10.7326/M19-3602
    1. Karmali RN, Skinner AC, Trogdon JG, Weinberger M, George SZ, Hassmiller Lich K. The association between the supply of select nonpharmacologic providers for pain and use of nonpharmacologic pain management services and initial opioid prescribing patterns for Medicare beneficiaries with persistent musculoskeletal pain. Health Serv Res 2021;56:275–88. 10.1111/1475-6773.13561
    1. Busse JW, Sadeghirad B, Oparin Y, et al. Management of acute pain from non-low back, musculoskeletal injuries: a systematic review and network meta-analysis of randomized trials. Ann Intern Med 2020;173:730–8. 10.7326/M19-3601
    1. American Dental Association. Statement on the use of opioids in the treatment of dental pain. Chicago, IL: American Dental Association; 2016.
    1. Teichman JM. Clinical practice. Acute renal colic from ureteral calculus. N Engl J Med 2004;350:684–93. 10.1056/NEJMcp030813
    1. Cordell WH, Larson TA, Lingeman JE, et al. Indomethacin suppositories versus intravenously titrated morphine for the treatment of ureteral colic. Ann Emerg Med 1994;23:262–9. 10.1016/S0196-0644(94)70038-9
    1. Cordell WH, Wright SW, Wolfson AB, et al. Comparison of intravenous ketorolac, meperidine, and both (balanced analgesia) for renal colic. Ann Emerg Med 1996;28:151–8. 10.1016/S0196-0644(96)70055-0
    1. Udén P, Rentzhog L, Berger T. A comparative study on the analgesic effects of indomethacin and hydromorphinechloride-atropine in acute, ureteral-stone pain. Acta Chir Scand 1983;149:497–9.
    1. Cole RS, Fry CH, Shuttleworth KE. The action of the prostaglandins on isolated human ureteric smooth muscle. Br J Urol 1988;61:19–26. 10.1111/j.1464-410X.1988.tb09155.x
    1. Food and Drug Administration. FDA approves new treatment for patients with migraine. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2019.
    1. Shapiro RE, Hochstetler HM, Dennehy EB, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain 2019;20:90. 10.1186/s10194-019-1044-6
    1. Buse DC, Reed ML, Fanning KM, Kurth T, Lipton RB. Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2017;57:31–44. 10.1111/head.12962
    1. Lipton RB, Reed ML, Kurth T, Fanning KM, Buse DC. Framingham-based cardiovascular risk estimates among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2017;57:1507–21. 10.1111/head.13179
    1. American College of Obstetricians and Gynecologists’ Committee on Clinical Consensus—Obstetrics. Pharmacologic stepwise multimodal approach for postpartum pain management: ACOG clinical consensus no. 1. Obstet Gynecol 2021;138:507–17. 10.1097/AOG.0000000000004517
    1. Chang AK, Bijur PE, Esses D, Barnaby DP, Baer J. Effect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department: a randomized clinical trial. JAMA 2017;318:1661–7. 10.1001/jama.2017.16190
    1. Friedman BW, Dym AA, Davitt M, et al. Naproxen with cyclobenzaprine, oxycodone/acetaminophen, or placebo for treating acute low back pain: a randomized clinical trial. JAMA 2015;314:1572–80. 10.1001/jama.2015.13043
    1. Lewis RA, Williams NH, Sutton AJ, et al. Comparative clinical effectiveness of management strategies for sciatica: systematic review and network meta-analyses. Spine J 2015;15:1461–77. 10.1016/j.spinee.2013.08.049
    1. Moore PA, Hersh EV. Combining ibuprofen and acetaminophen for acute pain management after third-molar extractions: translating clinical research to dental practice. J Am Dent Assoc 2013;144:898–908. 10.14219/jada.archive.2013.0207
    1. Pathan SA, Mitra B, Cameron PA. A systematic review and meta-analysis comparing the efficacy of nonsteroidal anti-inflammatory drugs, opioids, and paracetamol in the treatment of acute renal colic. Eur Urol 2018;73:583–95. 10.1016/j.eururo.2017.11.001
    1. Franklin GM, Stover BD, Turner JA, Fulton-Kehoe D, Wickizer TM; Disability Risk Identification Study Cohort. Early opioid prescription and subsequent disability among workers with back injuries: the Disability Risk Identification Study Cohort. Spine 2008;33:199–204. 10.1097/BRS.0b013e318160455c
    1. Webster BS, Verma SK, Gatchel RJ. Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery and late opioid use. Spine 2007;32:2127–32. 10.1097/BRS.0b013e318145a731
    1. Brummett CM, Waljee JF, Goesling J, et al. New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg 2017;152:e170504. 10.1001/jamasurg.2017.0504
    1. Goesling J, Moser SE, Zaidi B, et al. Trends and predictors of opioid use after total knee and total hip arthroplasty. Pain 2016;157:1259–65. 10.1097/j.pain.0000000000000516
    1. Johnson SP, Chung KC, Zhong L, et al. Risk of prolonged opioid use among opioid-naïve patients following common hand surgery procedures. J Hand Surg Am 2016;41:947–957.e3. 10.1016/j.jhsa.2016.07.113
    1. Lee JS, Hu HM, Edelman AL, et al. New persistent opioid use among patients with cancer after curative-intent surgery. J Clin Oncol 2017;35:4042–9. 10.1200/JCO.2017.74.1363
    1. Deyo RA, Hallvik SE, Hildebran C, et al. Use of prescription opioids before and after an operation for chronic pain (lumbar fusion surgery). Pain 2018;159:1147–54. 10.1097/j.pain.0000000000001202
    1. Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and risk factors for chronic opioid use among opioid-naive patients in the postoperative period. JAMA Intern Med 2016;176:1286–93. 10.1001/jamainternmed.2016.3298
    1. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004;62:788–90. 10.1212/01.WNL.0000113747.18760.D2
    1. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain 2016;17:131–57. Erratum in: J Pain 2016;17:508–10. 10.1016/j.jpain.2015.12.008
    1. Overton HN, Hanna MN, Bruhn WE, Hutfless S, Bicket MC, Makary MA; Opioids After Surgery Workgroup. Opioid-prescribing guidelines for common surgical procedures: an expert panel consensus. J Am Coll Surg 2018;227:411–8. 10.1016/j.jamcollsurg.2018.07.659
    1. Hill MV, Stucke RS, Billmeier SE, Kelly JL, Barth RJ Jr. Guideline for discharge opioid prescriptions after inpatient general surgical procedures. J Am Coll Surg 2018;226:996–1003. 10.1016/j.jamcollsurg.2017.10.012
    1. Michigan Opioid Prescribing Engagement Network. Prescribing recommendations. Ann Arbor, MI: Michigan Opioid Prescribing Engagement Network.
    1. Loder E, Weizenbaum E, Frishberg B, Silberstein S; American Headache Society Choosing Wisely Task Force. Choosing wisely in headache medicine: the American Headache Society’s list of five things physicians and patients should question. Headache 2013;53:1651–9. 10.1111/head.12233
    1. Langer-Gould AM, Anderson WE, Armstrong MJ, et al. The American Academy of Neurology’s top five choosing wisely recommendations. Neurology 2013;81:1004–11. 10.1212/WNL.0b013e31828aab14
    1. Food and Drug Administration. Disposal of unused medicines: what you should know. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2020.
    1. US Department of Veterans Affairs, US Department of Defense. VA/DoD clinical practice guideline for the use of opioids in the management of chronic pain. Washington, DC: US Department of Veterans Affairs; 2022.
    1. American College of Occupational and Environmental Medicine. Chronic pain guideline. Westminster, CO: ReedGroup; 2017.
    1. Federation of State Medical Boards. Guidelines for the chronic use of opioid analgesics. Euless, TX: Federation of State Medical Boards; 2017.
    1. Chou R, Qaseem A, Snow V, et al.; Clinical Efficacy Assessment Subcommittee of the American College of Physicians; American College of Physicians; American Pain Society Low Back Pain Guidelines Panel. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007;147:478–91. 10.7326/0003-4819-147-7-200710020-00006
    1. Hooten WM, Timming R, Belgrade M, et al.; Institute for Clinical Systems Improvement. Assessment and management of chronic pain.
    1. Fitzcharles M-A, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet 2021;397:2098–110. 10.1016/S0140-6736(21)00392-5
    1. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019;27:1578–89. 10.1016/j.joca.2019.06.011
    1. Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC. Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review. Spine 2014;39:556–63. 10.1097/BRS.0000000000000249
    1. Gaskell H, Moore RA, Derry S, Stannard C. Oxycodone for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014;6:CD010692.
    1. Goldenberg DL, Clauw DJ, Palmer RE, Clair AG. Opioid use in fibromyalgia: a cautionary tale. Mayo Clin Proc 2016;91:640–8. 10.1016/j.mayocp.2016.02.002
    1. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019;67:674–94. 10.1111/jgs.15767
    1. Hochberg MC, Altman RD, April KT, et al.; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64:465–74. 10.1002/acr.21596
    1. Hayden JA, van Tulder MW, Malmivaara A, Koes BW. Exercise therapy for treatment of non-specific low back pain. Cochrane Database Syst Rev 2005;(3):CD000335. 10.1002/14651858.CD000335.pub2
    1. Fransen M, McConnell S, Harmer AR, Van der Esch M, Simic M, Bennell KL. Exercise for osteoarthritis of the knee. Cochrane Database Syst Rev 2015;(1):CD004376.
    1. Fransen M, McConnell S, Hernandez-Molina G, Reichenbach S. Exercise for osteoarthritis of the hip. Cochrane Database Syst Rev 2014;(4):CD007912.
    1. Busch AJ, Barber KAR, Overend TJ, Peloso PMJ, Schachter CL. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev 2007;(4):CD003786.
    1. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 2017;76:318–28. 10.1136/annrheumdis-2016-209724
    1. Michelotti A, Iodice G, Vollaro S, Steenks MH, Farella M. Evaluation of the short-term effectiveness of education versus an occlusal splint for the treatment of myofascial pain of the jaw muscles. J Am Dent Assoc 2012;143:47–53. 10.14219/jada.archive.2012.0018
    1. List T, Axelsson S. Management of TMD: evidence from systematic reviews and meta-analyses. J Oral Rehabil 2010;37:430–51. 10.1111/j.1365-2842.2010.02089.x
    1. 2018 Physical Activity Guidelines Advisory Committee. 2018 Physical Activity Guidelines Advisory Committee scientific report. Washington, DC: US Department of Health and Human Services, Office of Disease Prevention and Health Promotion; 2018.
    1. Mannion AF, Müntener M, Taimela S, Dvorak J. A randomized clinical trial of three active therapies for chronic low back pain. Spine 1999;24:2435–48. 10.1097/00007632-199912010-00004
    1. Allen KD, Woolson S, Hoenig HM, et al. Stepped exercise program for patients with knee osteoarthritis: a randomized controlled trial. Ann Intern Med 2021;174:298–307. 10.7326/M20-4447
    1. Williams AC, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev 2012;(11):CD007407. 10.1002/14651858.CD007407.pub3
    1. Food and Drug Administration. FDA drug safety communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2015.
    1. Mujakperuo HR, Watson M, Morrison R, Macfarlane TV. Pharmacological interventions for pain in patients with temporomandibular disorders. Cochrane Database Syst Rev 2010;(10):CD004715. 10.1002/14651858.CD004715.pub2
    1. Kulkarni S, Thambar S, Arora H. Evaluating the effectiveness of nonsteroidal anti-inflammatory drug(s) for relief of pain associated with temporomandibular joint disorders: a systematic review. Clin Exp Dent Res 2020;6:134–46. 10.1002/cre2.241
    1. Howe CQ, Sullivan MD. The missing ‘P’ in pain management: how the current opioid epidemic highlights the need for psychiatric services in chronic pain care. Gen Hosp Psychiatry 2014;36:99–104. 10.1016/j.genhosppsych.2013.10.003
    1. Sullivan MD, Edlund MJ, Zhang L, Unützer J, Wells KB. Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med 2006;166:2087–93. 10.1001/archinte.166.19.2087
    1. Banerjee S, McCormack S. Medical cannabis for the treatment of chronic pain: a review of clinical effectiveness and guidelines. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2019.
    1. Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med 2009;24:733–8. 10.1007/s11606-009-0981-1
    1. Ostelo RWJG, Deyo RA, Stratford P, et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine 2008;33:90–4. 10.1097/BRS.0b013e31815e3a10
    1. Wallen M, Gillies D. Intra-articular steroids and splints/rest for children with juvenile idiopathic arthritis and adults with rheumatoid arthritis. Cochrane Database Syst Rev 2006;(1):CD002824. 10.1002/14651858.CD002824.pub2
    1. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006;(2):CD005328.
    1. Buchbinder R, Green S, Youd JM. Corticosteroid injections for shoulder pain. Cochrane Database Syst Rev 2003;(1):CD004016.
    1. Chou R, Fu R, Dana T, Pappas M, Hart E, Mauer K. Interventional treatments for acute and chronic pain: systematic review [Internet]. Comparative effectiveness review no. 247. AHRQ publication no. 21–EHC030. Rockville, MD: Agency for Healthcare Research and Quality; 2021.
    1. Food and Drug Administration. FDA drug safety communication: FDA requires label changes to warn of rare but serious neurologic problems after epidural corticosteroid injections for pain. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2014.
    1. Interagency Pain Research Coordinating Committee. National pain strategy: a comprehensive population health-level strategy for pain. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 2015.
    1. Miller M, Barber CW, Leatherman S, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med 2015;175:608–15. 10.1001/jamainternmed.2014.8071
    1. Food and Drug Administration. FDA blueprint for prescriber education for extended-release and long-acting opioid analgesics. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2017.
    1. Von Korff M, Merrill JO, Rutter CM, Sullivan M, Campbell CI, Weisner C. Time-scheduled vs. pain-contingent opioid dosing in chronic opioid therapy. Pain 2011;152:1256–62. 10.1016/j.pain.2011.01.005
    1. Food and Drug Administration. Abuse-deterrent opioids—evaluation and labeling: guidance for industry. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2015.
    1. Paulozzi L, Mack K, Jones C; CDC. Vital signs: risk for overdose from methadone used for pain relief—United States, 1999–2010. MMWR Morb Mortal Wkly Rep 2012;61:493–7.
    1. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 2005;19:13–24. 10.1080/J354v19n04_05
    1. Grissinger M. Keeping patients safe from methadone overdoses. P T 2011;36:462–6.
    1. Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Health Syst Pharm 2009;66:825–33. 10.2146/ajhp070392
    1. Chou R, Cruciani RA, Fiellin DA, et al.; American Pain Society; Heart Rhythm Society. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain 2014;15:321–37. 10.1016/j.jpain.2014.01.494
    1. Coyle DT, Pratt C-Y, Ocran-Appiah J, Secora A, Kornegay C, Staffa J. Opioid analgesic dose and the risk of misuse, overdose, and death: a narrative review. Pharmacoepidemiol Drug Saf 2018;27:464–72. 10.1002/pds.4366
    1. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010;152:85–92. 10.7326/0003-4819-152-2-201001190-00006
    1. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011;171:686–91. 10.1001/archinternmed.2011.117
    1. Bohnert ASB, Logan JE, Ganoczy D, Dowell D. A detailed exploration into the association of prescribed opioid dosage and overdose deaths among patients with chronic pain. Med Care 2016;54:435–41. 10.1097/MLR.0000000000000505
    1. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006;96:627–32. 10.1093/bja/ael051
    1. Dasgupta N, Wang Y, Bae J, et al. Inches, centimeters, and yards: overlooked definition choices inhibit interpretation of morphine equivalence. Clin J Pain 2021;37:565–74.
    1. SpecGx LLC. Hydrocodone bitartrate and acetaminophen–hydrocodone bitartrate and acetaminophen tablet.
    1. State of Washington Department of Health. Provider letter: clarification of opioid prescribing rules. Olympia, WA: State of Washington Department of Health; 2019.
    1. Kaplovitch E, Gomes T, Camacho X, Dhalla IA, Mamdani MM, Juurlink DN. Sex differences in dose escalation and overdose death during chronic opioid therapy: a population-based cohort study. PLoS One 2015;10:e0134550. 10.1371/journal.pone.0134550
    1. Agnoli A, Xing G, Tancredi DJ, Magnan E, Jerant A, Fenton JJ. Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids. JAMA 2021;326:411–9. 10.1001/jama.2021.11013
    1. Hallvik SE, El Ibrahimi S, Johnston K, et al. Patient outcomes after opioid dose reduction among patients with chronic opioid therapy. Pain 2022;163:83–90. 10.1097/j.pain.0000000000002298
    1. Perez HR, Buonora M, Cunningham CO, Heo M, Starrels JL. Opioid taper is associated with subsequent termination of care: a retrospective cohort study. J Gen Intern Med 2020;35:36–42. 10.1007/s11606-019-05227-9
    1. Glanz JM, Binswanger IA, Shetterly SM, Narwaney KJ, Xu S. Association between opioid dose variability and opioid overdose among adults prescribed long-term opioid therapy. JAMA Netw Open 2019;2:e192613. 10.1001/jamanetworkopen.2019.2613
    1. Oliva EM, Bowe T, Manhapra A, et al. Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ 2020;368:m283. 10.1136/bmj.m283
    1. Fenton JJ, Magnan E, Tseregounis IE, Xing G, Agnoli AL, Tancredi DJ. Long-term risk of overdose or mental health crisis after opioid dose tapering. JAMA Netw Open 2022;5:e2216726. 10.1001/jamanetworkopen.2022.16726
    1. Binswanger IA, Glanz JM, Faul M, et al. The association between opioid discontinuation and heroin use: a nested case-control study. Drug Alcohol Depend 2020;217:108248. 10.1016/j.drugalcdep.2020.108248
    1. Lagisetty P, Zhang K, Haffajee RL, et al. Opioid prescribing history prior to heroin overdose among commercially insured adults. Drug Alcohol Depend 2020;212:108061. 10.1016/j.drugalcdep.2020.108061
    1. Frank JW, Lovejoy TI, Becker WC, et al. Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: a systematic review. Ann Intern Med 2017;167:181–91. 10.7326/M17-0598
    1. US Department of Health and Human Services Working Group on Patient-Centered Reduction or Discontinuation of Long-term Opioid Analgesics. HHS guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. Rockville, MD: US Department of Health and Human Services; 2019.
    1. Substance Abuse and Mental Health Services Administration. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS publication no. (SMA) 18–5054. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 2018.
    1. Ecker J, Abuhamad A, Hill W, et al. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine. Am J Obstet Gynecol 2019;221:B5–28. 10.1016/j.ajog.2019.03.022
    1. Haque W, Watson DJ, Bryant SG. Death following suspected alprazolam withdrawal seizures: a case report. Tex Med 1990;86:44–7.
    1. Lann MA, Molina DK. A fatal case of benzodiazepine withdrawal. Am J Forensic Med Pathol 2009;30:177–9. 10.1097/PAF.0b013e3181875aa0
    1. Dowell D, Haegerich TM. Changing the conversation about opioid tapering. Ann Intern Med 2017;167:208–9. 10.7326/M17-1402
    1. Berna C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic noncancer pain: evidence and recommendations for everyday practice. Mayo Clin Proc 2015;90:828–42. 10.1016/j.mayocp.2015.04.003
    1. Darnall BD, Ziadni MS, Stieg RL, Mackey IG, Kao M-C, Flood P. Patient-centered prescription opioid tapering in community outpatients with chronic pain. JAMA Intern Med 2018;178:707–8. 10.1001/jamainternmed.2017.8709
    1. Goesling J, DeJonckheere M, Pierce J, et al. Opioid cessation and chronic pain: perspectives of former opioid users. Pain 2019;160:1131–45. 10.1097/j.pain.0000000000001493
    1. Sullivan MD, Turner JA, DiLodovico C, D’Appollonio A, Stephens K, Chan Y-F. Prescription opioid taper support for outpatients with chronic pain: a randomized controlled trial. J Pain 2017;18:308–18. 10.1016/j.jpain.2016.11.003
    1. Manhapra A, Arias AJ, Ballantyne JC. The conundrum of opioid tapering in long-term opioid therapy for chronic pain: a commentary. Subst Abus 2018;39:152–61. 10.1080/08897077.2017.1381663
    1. Sturgeon JA, Sullivan MD, Parker-Shames S, Tauben D, Coelho P. Outcomes in long-term opioid tapering and buprenorphine transition: a retrospective clinical data analysis. Pain Med 2020;21:3635–44. 10.1093/pm/pnaa029
    1. Sullivan MD. Depression effects on long-term prescription opioid use, abuse, and addiction. Clin J Pain 2018;34:878–84. 10.1097/AJP.0000000000000603
    1. US Department of Veterans Affairs, Pharmacy Benefits Management, National Academic Detailing Services. Pain management opioid taper decision tool: a VA clinician’s guide. Washington, DC: US Department of Veterans Affairs; 2016.
    1. Henry SG, Paterniti DA, Feng B, et al. Patients’ experience with opioid tapering: a conceptual model with recommendations for clinicians. J Pain 2019;20:181–91. 10.1016/j.jpain.2018.09.001
    1. Rich RC, Chou R, Mariano ER, Dopp AL, Sullenger R, Burstin H; Pain Management Guidelines and Evidence Standards Working Group. Best practices, research gaps, and future priorities to support tapering patients on long-term opioid therapy for chronic non-cancer pain in outpatient settings. NAM Perspect 2020;2020:10.31478/202008c. 10.31478/202008c
    1. Berlin D, Farmer B, Rao R, et al.; CDC. Deaths and severe adverse events associated with anesthesia-assisted rapid opioid detoxification—New York City, 2012. MMWR Morb Mortal Wkly Rep 2013;62:777–80.
    1. Gowing L, Farrell M, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2016;(5):CD002024. 10.1002/14651858.CD002024.pub5
    1. Chou R, Ballantyne J, Lembke A. Rethinking opioid dose tapering, prescription opioid dependence, and indications for buprenorphine. Ann Intern Med 2019;171:427–9. 10.7326/M19-1488
    1. Fishman MA, Kim PS. Buprenorphine for chronic pain: a systemic review. Curr Pain Headache Rep 2018;22:83. 10.1007/s11916-018-0732-2
    1. Pade PA, Cardon KE, Hoffman RM, Geppert CMA. Prescription opioid abuse, chronic pain, and primary care: a co-occurring disorders clinic in the chronic disease model. J Subst Abuse Treat 2012;43:446–50. 10.1016/j.jsat.2012.08.010
    1. Paone D, Tuazon E, Stajic M, et al. Buprenorphine infrequently found in fatal overdose in New York City. Drug Alcohol Depend 2015;155:298–301. 10.1016/j.drugalcdep.2015.08.007
    1. Cohen SM, Weimer MB, Levander XA, Peckham AM, Tetrault JM, Morford KL. Low dose initiation of buprenorphine: a narrative review and practical approach. J Addict Med 2022;16:399–406. 10.1097/ADM.0000000000000945
    1. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006;144:127–34. 10.7326/0003-4819-144-2-200601170-00010
    1. Lagisetty PA, Healy N, Garpestad C, Jannausch M, Tipirneni R, Bohnert ASB. Access to primary care clinics for patients with chronic pain receiving opioids. JAMA Netw Open 2019;2:e196928. 10.1001/jamanetworkopen.2019.6928
    1. Mundkur ML, Franklin JM, Abdia Y, et al. Days’ supply of initial opioid analgesic prescriptions and additional fills for acute pain conditions treated in the primary care setting—United States, 2014. MMWR Morb Mortal Wkly Rep 2019;68:140–3. 10.15585/mmwr.mm6806a3
    1. Coste J, Delecoeuillerie G, Cohen de Lara A, Le Parc JM, Paolaggi JB. Clinical course and prognostic factors in acute low back pain: an inception cohort study in primary care practice. BMJ 1994;308:577–80. 10.1136/bmj.308.6928.577
    1. McCarthy DM, Kim HS, Hur SI, et al. Patient-reported opioid pill consumption after an ED visit: how many pills are people using? Pain Med 2021;22:292–302. 10.1093/pm/pnaa048
    1. Daoust R, Paquet J, Cournoyer A, et al. Quantity of opioids consumed following an emergency department visit for acute pain: a Canadian prospective cohort study. BMJ Open 2018;8:e022649. 10.1136/bmjopen-2018-022649
    1. Robinson KA, Thiels CA, Stokes S, et al. Comparing clinician consensus recommendations to patient-reported opioid use across multiple hospital systems. Ann Surg 2022;275:e361–5. 10.1097/SLA.0000000000003986
    1. Mallama CA, Greene C, Alexandridis AA, McAninch JK, Dal Pan G, Meyer T. Patient-reported opioid analgesic use after discharge from surgical procedures: a systematic review. Pain Med 2022;23:29–44. 10.1093/pm/pnab244
    1. Thiels CA, Ubl DS, Yost KJ, et al. Results of a prospective, multicenter initiative aimed at developing opioid-prescribing guidelines after surgery. Ann Surg 2018;268:457–68. 10.1097/SLA.0000000000002919
    1. Reznikoff C. How acute pain leads to chronic opioid use. Cleve Clin J Med 2018;85:837–41. 10.3949/ccjm.85a.18038
    1. Brat GA, Agniel D, Beam A, et al. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. BMJ 2018;360:j5790. 10.1136/bmj.j5790
    1. Bartels K, Mayes LM, Dingmann C, Bullard KJ, Hopfer CJ, Binswanger IA. Opioid use and storage patterns by patients after hospital discharge following surgery. PLoS One 2016;11:e0147972. 10.1371/journal.pone.0147972
    1. Bicket MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL. Prescription opioid analgesics commonly unused after surgery: a systematic review. JAMA Surg 2017;152:1066–71. 10.1001/jamasurg.2017.0831
    1. Neuman MD, Bateman BT, Wunsch H. Inappropriate opioid prescription after surgery. Lancet 2019;393:1547–57. 10.1016/S0140-6736(19)30428-3
    1. Joo SS, Hunter OO, Tamboli M, et al. Implementation of a patient-specific tapering protocol at discharge decreases total opioid dose prescribed for 6 weeks after elective primary spine surgery. Reg Anesth Pain Med 2020;45:474–8. 10.1136/rapm-2020-101324
    1. Tamboli M, Mariano ER, Gustafson KE, et al. A multidisciplinary patient-specific opioid prescribing and tapering protocol is associated with a decrease in total opioid dose prescribed for six weeks after total hip arthroplasty. Pain Med 2020;21:1474–81. 10.1093/pm/pnz260
    1. Kalso E, Simpson KH, Slappendel R, Dejonckheere J, Richarz U. Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine. BMC Med 2007;5:39. 10.1186/1741-7015-5-39
    1. DeRigne L, Stoddard-Dare P, Collins C, Quinn L. Paid sick leave and preventive health care service use among U.S. working adults. Prev Med 2017;99:58–62. 10.1016/j.ypmed.2017.01.020
    1. Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the Drug Abuse Screening Test. J Subst Abuse Treat 2007;32:189–98. 10.1016/j.jsat.2006.08.002
    1. McNeely J, Wu L-T, Subramaniam G, et al. Performance of the Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) tool for substance use screening in primary care patients. Ann Intern Med 2016;165:690–9. 10.7326/M16-0317
    1. Reinert DF, Allen JP. The alcohol use disorders identification test: an update of research findings. Alcohol Clin Exp Res 2007;31:185–99. 10.1111/j.1530-0277.2006.00295.x
    1. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998;158:1789–95. 10.1001/archinte.158.16.1789
    1. Zedler B, Xie L, Wang L, et al. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. Pain Med 2014;15:1911–29. 10.1111/pme.12480
    1. Broussard CS, Rasmussen SA, Reefhuis J, et al.; National Birth Defects Prevention Study. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 2011;204:314.e1–11. 10.1016/j.ajog.2010.12.039
    1. Lind JN, Interrante JD, Ailes EC, et al. Maternal use of opioids during pregnancy and congenital malformations: a systematic review. Pediatrics 2017;139:e20164131. 10.1542/peds.2016-4131
    1. Yazdy MM, Desai RJ, Brogly SB. Prescription opioids in pregnancy and birth outcomes: a review of the literature. J Pediatr Genet 2015;4:56–70. 10.1055/s-0035-1556740
    1. Yazdy MM, Mitchell AA, Tinker SC, Parker SE, Werler MM. Periconceptional use of opioids and the risk of neural tube defects. Obstet Gynecol 2013;122:838–44. 10.1097/AOG.0b013e3182a6643c
    1. Hadi I, da Silva O, Natale R, Boyd D, Morley-Forster PK. Opioids in the parturient with chronic nonmalignant pain: a retrospective review. J Opioid Manag 2006;2:31–4. 10.5055/jom.2006.0005
    1. Sinclair DC 2nd, Hegmann KT, Holland JP. Acceptable risk of sudden incapacitation among safety critical transportation workers: a comprehensive synthesis. J Occup Environ Med 2021;63:329–42. 10.1097/JOM.0000000000002140
    1. Edlund MJ, Steffick D, Hudson T, Harris KM, Sullivan M. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain 2007;129:355–62. 10.1016/j.pain.2007.02.014
    1. Turner BJ, Liang Y. Drug overdose in a retrospective cohort with non-cancer pain treated with opioids, antidepressants, and/or sedative-hypnotics: interactions with mental health disorders. J Gen Intern Med 2015;30:1081–96. 10.1007/s11606-015-3199-4
    1. Larochelle MR, Liebschutz JM, Zhang F, Ross-Degnan D, Wharam JF. Opioid prescribing after nonfatal overdose and association with repeated overdose: a cohort study. Ann Intern Med 2016;164:1–9. 10.7326/M15-0038
    1. American College of Obstetricians and Gynecologists Committee on Obstetric Practice, American Society of Addiction Medicine. ACOG committee opinion no. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol 2017;130:e81–94. 10.1097/AOG.0000000000002235
    1. Whiteman VE, Salemi JL, Mogos MF, Cain MA, Aliyu MH, Salihu HM. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. J Pregnancy 2014;2014:906723. 10.1155/2014/906723
    1. American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine. Obstetric care consensus no. 8: interpregnancy care. Obstet Gynecol 2019;133:e51–72. 10.1097/AOG.0000000000003025
    1. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 762: prepregnancy counseling. Obstet Gynecol 2019;133:e78–89. 10.1097/AOG.0000000000003013
    1. American College of Obstetricians and Gynecologists’ Committee on Health Care for Underserved Women, Contraceptive Equity Expert Work Group, and Committee on Ethics. Patient-centered contraceptive counseling: ACOG committee statement number 1. Obstet Gynecol 2022;139:350–3. 10.1097/AOG.0000000000004659
    1. American Medical Association Opioid Task Force. 2019 recommendations of the AMA Opioid Task Force. Chicago, IL: American Medical Association; 2019.
    1. Patrick SW, Barfield WD, Poindexter BB, et al.; Committee on Fetus and Newborn, Committee on Substance Use and Prevention. Neonatal opioid withdrawal syndrome. Pediatrics 2020;146:e2020029074. 10.1542/peds.2020-029074
    1. Goodman LS, Limberd LE. Goodman and Gilman’s the pharmacologic basis of therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996.
    1. Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology. JAMA 1998;279:1877–82. 10.1001/jama.279.23.1877
    1. Hegmann KT, Weiss MS, Bowden K, et al. ACOEM practice guidelines: opioids and safety-sensitive work. J Occup Environ Med 2014;56:e46–53. 10.1097/JOM.0000000000000237
    1. Kroenke K, Spitzer RL, Williams JBW, Löwe B. The Patient Health Questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry 2010;32:345–59. 10.1016/j.genhosppsych.2010.03.006
    1. Reid MC, Engles-Horton LL, Weber MB, Kerns RD, Rogers EL, O’Connor PG. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med 2002;17:173–9. 10.1046/j.1525-1497.2002.10435.x
    1. Edlund MJ, Martin BC, Devries A, Fan M-Y, Braden JB, Sullivan MD. Trends in use of opioids for chronic noncancer pain among individuals with mental health and substance use disorders: the TROUP study. Clin J Pain 2010;26:1–8. 10.1097/AJP.0b013e3181b99f35
    1. Gladden RM, O’Donnell J, Mattson CL, Seth P. Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine—25 states, July–December 2017 to January–June 2018. MMWR Morb Mortal Wkly Rep 2019;68:737–44. 10.15585/mmwr.mm6834a2
    1. Jones CM, Paulozzi LJ, Mack KA; CDC. Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths—United States, 2010. MMWR Morb Mortal Wkly Rep 2014;63:881–5.
    1. Krist AH, Davidson KW, Mangione CM, et al.; US Preventive Services Task Force. Krist AH, Davidson KW, Mangione CM. Screening for unhealthy drug use: US Preventive Services Task Force recommendation statement. JAMA 2020;323:2301–9. 10.1001/jama.2020.8020
    1. Saitz R, Cheng DM, Allensworth-Davies D, Winter MR, Smith PC. The ability of single screening questions for unhealthy alcohol and other drug use to identify substance dependence in primary care. J Stud Alcohol Drugs 2014;75:153–7. 10.15288/jsad.2014.75.153
    1. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med 2010;170:1155–60. 10.1001/archinternmed.2010.140
    1. Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med 2018;169:137–45. 10.7326/M17-3107
    1. Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013;346(jan30 5):f174. 10.1136/bmj.f174
    1. Enteen L, Bauer J, McLean R, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health 2010;87:931–41. 10.1007/s11524-010-9495-8
    1. Coffin PO, Behar E, Rowe C, et al. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med 2016;165:245–52. 10.7326/M15-2771
    1. Chua K-P, Brummett CM, Ng S, Bohnert ASB. Association between receipt of overlapping opioid and benzodiazepine prescriptions from multiple prescribers and overdose risk. JAMA Netw Open 2021;4:e2120353. 10.1001/jamanetworkopen.2021.20353
    1. Lin DH, Lucas E, Murimi IB, et al. Physician attitudes and experiences with Maryland’s prescription drug monitoring program (PDMP). Addiction 2017;112:311–9. 10.1111/add.13620
    1. US Government Accountability Office. Report to congressional committees. Prescription drug monitoring programs: views on usefulness and challenges of programs. GAO-21–22. Washington, DC: US Government Accountability Office; 2020.
    1. CDC. Integrating & expanding prescription drug monitoring program data: lessons from nine states. Atlanta, GA: US Department of Health and Human Services, CDC; 2017.
    1. Irvine JM, Hallvik SE, Hildebran C, Marino M, Beran T, Deyo RA. Who uses a prescription drug monitoring program and how? Insights from a statewide survey of Oregon clinicians. J Pain 2014;15:747–55. 10.1016/j.jpain.2014.04.003
    1. Lee B, Zhao W, Yang K-C, Ahn Y-Y, Perry BL. Systematic evaluation of state policy interventions targeting the US opioid epidemic, 2007–2018. JAMA Netw Open 2021;4:e2036687. 10.1001/jamanetworkopen.2020.36687
    1. Oliva JD. Dosing discrimination: regulating PDMP risk scores. Calif Law Rev 2022;110:1–47. .
    1. Cochran G, Brown J, Yu Z, et al. Validation and threshold identification of a prescription drug monitoring program clinical opioid risk metric with the WHO alcohol, smoking, and substance involvement screening test. Drug Alcohol Depend 2021;228:109067. 10.1016/j.drugalcdep.2021.109067
    1. Cone EJ, Huestis MA. Interpretation of oral fluid tests for drugs of abuse. Ann N Y Acad Sci 2007;1098:51–103. 10.1196/annals.1384.037
    1. Substance Abuse and Mental Health Services Administration, US Department of Health and Human Services. Mandatory guidelines for federal workplace drug testing programs—oral/fluid. 84 Fed. Reg. 57554–600 (October 25, 2019).
    1. Starrels JL, Fox AD, Kunins HV, Cunningham CO. They don’t know what they don’t know: internal medicine residents’ knowledge and confidence in urine drug test interpretation for patients with chronic pain. J Gen Intern Med 2012;27:1521–7. 10.1007/s11606-012-2165-7
    1. Chua I, Petrides AK, Schiff GD, et al. Provider misinterpretation, documentation, and follow-up of definitive urine drug testing results. J Gen Intern Med 2020;35:283–90. 10.1007/s11606-019-05514-5
    1. Washington State Agency Medical Directors’ Group. AMDG 2015 interagency guideline on prescribing opioids for pain. Olympia, WA: Washington State Agency Medical Directors’ Group; 2015.
    1. Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med 2015;49:493–501. 10.1016/j.amepre.2015.03.040
    1. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med 2016;17:85–98.
    1. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert ASB. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ 2015;350(jun10 9):h2698. 10.1136/bmj.h2698
    1. Food and Drug Administration. FDA drug safety communication: FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) when used with CNS depressants or in patients with lung problems. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2019.
    1. Food and Drug Administration. FDA drug safety communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2017.
    1. US Department of Veterans Affairs, Pharmacy Benefits Management, National Academic Detailing Services. Re-evaluating the use of benzodiazepines: a quick reference guide. Washington, DC: US Department of Veterans Affairs; 2016.
    1. Paquin AM, Zimmerman K, Rudolph JL. Risk versus risk: a review of benzodiazepine reduction in older adults. Expert Opin Drug Saf 2014;13:919–34. 10.1517/14740338.2014.925444
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. Washington, DC: American Psychiatric Association; 2000.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
    1. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015;156:569–76. 10.1097/01.j.pain.0000460357.01998.f1
    1. Boscarino JA, Withey CA, Dugan RJ, Hu Y, Auciello J, Alfieri T. Opioid medication use among chronic non-cancer pain patients assessed with a modified drug effects questionnaire and the association with opioid use disorder. J Pain Res 2020;13:2697–705. 10.2147/JPR.S275397
    1. Von Korff M, Walker RL, Saunders K, et al. Prevalence of prescription opioid use disorder among chronic opioid therapy patients after health plan opioid dose and risk reduction initiatives. Int J Drug Policy 2017;46:90–8. 10.1016/j.drugpo.2017.05.053
    1. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014;(6):CD002207. 10.1002/14651858.CD002207.pub4
    1. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;(3):CD002209. 10.1002/14651858.CD002209.pub2
    1. Fullerton CA, Kim M, Thomas CP, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv 2014;65:146–57. 10.1176/appi.ps.201300235
    1. Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O’Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med 2014;174:1947–54. 10.1001/jamainternmed.2014.5302
    1. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011;68:1238–46. 10.1001/archgenpsychiatry.2011.121
    1. Varisco T, Shen C, Thornton D. Chronic prescription opioid use predicts stabilization on buprenorphine for the treatment of opioid use disorder. J Subst Abuse Treat 2020;117:108073. 10.1016/j.jsat.2020.108073
    1. Blondell RD, Ashrafioun L, Dambra CM, Foschio EM, Zielinski AL, Salcedo DM. A clinical trial comparing tapering doses of buprenorphine with steady doses for chronic pain and co-existent opioid addiction. J Addict Med 2010;4:140–6. 10.1097/ADM.0b013e3181ba895d
    1. Neumann AM, Blondell RD, Jaanimägi U, et al. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis 2013;32:68–78. 10.1080/10550887.2012.759872
    1. Krawczyk N, Mojtabai R, Stuart EA, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction 2020;115:1683–94. 10.1111/add.14991
    1. Pearce LA, Min JE, Piske M, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ 2020;368:m772. 10.1136/bmj.m772
    1. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011;377:1506–13. 10.1016/S0140-6736(11)60358-9
    1. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011;(2):CD001333.
    1. Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 2018;391:309–18. 10.1016/S0140-6736(17)32812-X
    1. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2011;(9):CD005031. 10.1002/14651858.CD005031.pub4
    1. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007;11:1–171, iii–iv. 10.3310/hta11090
    1. Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder. Treatment Improvement Protocol (TIP) series 63 publication no. PEP21–02–01–002. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 2021.
    1. Link HM, Jones H, Miller L, Kaltenbach K, Seligman N. Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis. Am J Obstet Gynecol MFM 2020;2:100179. 10.1016/j.ajogmf.2020.100179
    1. Office of the Secretary, US Department of Health and Human Services. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. 86 Fed. Reg. 22439–40.
    1. Substance Abuse and Mental Health Services Administration. Medication-assisted treatment: become a buprenorphine waivered practitioner. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 2021.
    1. Indivior Inc. Suboxone medication guide. Reference ID: 4055394; revised Feb. 2017. North Chesterfield, VA: Indivior; 2017.
    1. Indivior Inc. Sublocade medication guide. Reference ID: 4555989. North Chesterfield, VA: Indivior; 2020.
    1. Randhawa PA, Brar R, Nolan S. Buprenorphine-naloxone “microdosing”: an alternative induction approach for the treatment of opioid use disorder in the wake of North America’s increasingly potent illicit drug market. CMAJ 2020;192:E73. 10.1503/cmaj.74018
    1. Robbins JL, Englander H, Gregg J. Buprenorphine microdose induction for the management of prescription opioid dependence. J Am Board Fam Med 2021;34(Suppl):S141–6. 10.3122/jabfm.2021.S1.200236
    1. Lee JD, Vocci F, Fiellin DA. Unobserved “home” induction onto buprenorphine. J Addict Med 2014;8:299–308. 10.1097/ADM.0000000000000059
    1. Houry D. Letter to American Society of Addiction Medicine (ASAM) on buprenorphine and CDC’s guideline. Atlanta, GA: US Department of Health and Human Services, CDC; 2018.
    1. Code of Federal Regulations. Title 21. Chapter 2. Part 1306. General Information. §1306.07.
    1. H.R. 8900—116th Congress (2019–2020): Further Continuing Appropriations Act, 2021, and Other Extensions Act. 2020 Dec 11.
    1. US Department of Justice Drug Enforcement Administration, Diversion Control Division. Registration: instructions to request exception to 21 CFR 1306.07(b) 3-day rule (EO-DEA248). Springfield, VA: US Department of Justice Drug Enforcement Administration, Diversion Control Division; 2022.
    1. Hawk K, Hoppe J, Ketcham E, et al. Consensus recommendations on the treatment of opioid use disorder in the emergency department. Ann Emerg Med 2021;78:434–42. 10.1016/j.annemergmed.2021.04.023
    1. Alkermes. Vivitrol. Full prescribing information. Dublin, Ireland: Alkermes; 2021.
    1. Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health 2015;105:e55–63. 10.2105/AJPH.2015.302664
    1. Hruschak V, Cochran G, Wasan AD. Psychosocial interventions for chronic pain and comorbid prescription opioid use disorders: a narrative review of the literature. J Opioid Manag 2018;14:345–58. 10.5055/jom.2018.0467
    1. Dowell D, Compton WM, Giroir BP. Patient-centered reduction or discontinuation of long-term opioid analgesics: the HHS guide for clinicians. JAMA 2019;322:1855–6. 10.1001/jama.2019.16409
    1. Agency for Healthcare Research and Quality. About SDOH in healthcare. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2020.
    1. Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. Unequal treatment: confronting racial and ethnic disparities in health care. Smedley BD, Stith AY, Nelson AR, eds. Washington, DC: National Academies Press; 2003.
    1. CDC. CDC COVID-19 response health equity strategy: accelerating progress towards reducing COVID-19 disparities and achieving health equity. Atlanta, GA: US Department of Health and Human Services, CDC; 2020.
    1. Ancker JS, Gossey JT, Nosal S, et al. Effect of an electronic health record “nudge” on opioid prescribing and electronic health record keystrokes in ambulatory care. J Gen Intern Med 2021;36:430–7. 10.1007/s11606-020-06276-1
    1. Montoy JCC, Coralic Z, Herring AA, Clattenburg EJ, Raven MC. Association of default electronic medical record settings with health care professional patterns of opioid prescribing in emergency departments: a randomized quality improvement study. JAMA Intern Med 2020;180:487–93. 10.1001/jamainternmed.2019.6544
    1. National Academies of Sciences, Engineering, and Medicine. Pain management and the opioid epidemic: balancing societal and individual benefits and risks of prescription opioid use. Washington, DC: National Academies Press; 2017.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner